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GLUTATHIONE CONJUGATION OF A COCAINE PYROLYSIS 
PRODUCT AEME AND RELATED COMPOUNDS 
 
Alan Lewis Myers 
 
 
 Free-base (crack) cocaine smoking continues to be a popular method of drug abuse in 
the United States.  Pyrolysis of free-base cocaine readily occurs, forming primarily benzoic 
acid and anhydroecgonine methyl ester (AEME), which structurally contains an α,β-
unsaturated carbonyl functional group.  This electrophilic structure is suggestive of chemical 
reactivity with ubiquitously occurring cellular nucleophiles, such as glutathione.  Glutathione 
adducts formed in vivo are metabolized to N-acetylcysteine derivatives by the enzymatically 
driven mercapturic acid pathway.  AEME and its transesterification product in the presence of 
ethanol, anhydroecgonine ethyl ester (AEEE), were synthesized from cocaine hydrochloride.  
Glutathione (GSH) and mercapturic acid (NAC) conjugates of AEME were synthesized, and 
the stereochemistry of the AEME-NAC conjugate was structurally elucidated by NMR and 
mass spectrometry.  Using Ellmans method to monitor glutathione depletion over time, 
AEME reacted with GSH at a slower rate (6.8 x 10-3 mM-1min-1) than equimolar concentrations 
of arecoline or ethacrynic acid (2.2 × 10-1 mM-1min-1 and 4.1 × 10-1 mM-1min-1, respectively).  
AEME also reduced the chemical formation of the DCNB-SG conjugate.  In pooled human 
liver cytosol, the incubation of AEME with GSH at 37°C for 60 minutes at different pH levels 
was analyzed by LC-MS.  We found unequivocal data suggesting enzymatic catalysis of 
AEME to AEME-SG in the presence of reduced GSH.  However, AEME (10 mM) 
significantly reduced GST activity (p < 0.005) following a 20 hour incubation with HLC (1 
mg).  Additionally, AEME exhibited mixed-linear inhibition (Ki = 334 µM) towards cytosolic 
GST activity.  A solid phase extraction (SPE) method was developed to extract cocaine and 
cocaine metabolites from urine.  We identified approximately 50 ng/mL of AEEE by LC-MS 
in the urine of a known freebase cocaine/ethanol abuser, and additionally confirmed the 
structure of the metabolite by LC-MS/MS.  This SPE method is useful in detecting AEME 
conjugates in biological fluids.  We studied the cytotoxicity of pyrolysis products on A549 
lung fibroblasts using trypan blue exclusion and flow cytometry.  To summarize, our work 
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 Cocaine (Fig 1.1) is a naturally occurring alkaloid with a concentration of 
approximately 1% within the leaves of the coca plant (Erythroxylon coca), a tree indigenous to 
mountainous regions of Peru and Bolivia (1).  Use of the drug for recreational, medicinal and 
religious purposes has dated back thousands of years.  Native Indians of South America are 
often recognized as the first known tribal group to chew the coca leaves for its mild stimulatory 
effects (2).  During the late nineteenth century, cocaine hydrochloride was first isolated from 
coca leaves and the extraction of pure cocaine was then possible.  The first cocaine epidemic to 
strike the United States, according to one author, occurred in the late 1880s (2).  During this 
time, cocaine was widely used and touted as a panacea for many illnesses (2).  Sigmund Freud, 
a prominent psychiatrist, recommended in his paper entitled On Cocaine that cocaine be used 
as a local anesthetic, an aphrodisiac and as a primary pharmacologic agent in treating 
depression, alcoholism and morphine addiction (2).  Cocaine was available in a variety of 
products during this time, including patent medicines, tonics and soft drinks.   
John Styth, an apothecary, formulated the syrup base for Coca-Cola in 1886 using a 
compounded mixture of coca plant extract with an extract from the African kola nut, also a 
stimulant (2).  Later, Styth marketed the drink as a medicine.  Inhalation of burning coca leaves 
or smoking coca evolved slowly and remained major modes of medicinal and recreational use 
around this time (3).  In 1903 the dangers of cocaine were publicized and cocaine was removed 
from the Coca-Cola formulation (2).  Federal legislation soon followed with the enactment of 
the Pure Food and Drug Act of 1906 and the Harrison Narcotic Act of 1914 (3).  This 
legislation curtailed the distribution and use of coca leaves and coca products, listing cocaine 
as a narcotic (2).  Although legislation made cocaine use legal solely through a physicians 
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prescription, cocaine use ironically diverged to intravenous and intranasal abuse since these 
forms were now readily available (3).    
Cocaine HCl was typically smoked as a cigarette or in a pipe with marijuana, tobacco 
or other herbs (3).  Achieving only mild effects from smoking the hydrochloride salt, users 
found smoking coca paste (crude extract containing free alkaloids) and later cocaine free-base 
(crack cocaine) to produce more pleasurable effects (3).  In the early 1970s, cocaine abuse re-
emerged, particularly among middle-class Americans, and reached epidemic status in the early 
1980s (2).  In 1985, one survey found that cocaine use peaked in U.S. society with 
approximately 5.8 million chronic cocaine users (2).  This number decreased over the next 
decade as surveys from 1991 and 1994 revealed around 1.9 million and 1.4 million, 
respectively, cocaine users in society (2).  Most of the sampled cocaine abusers were between 
18-34 years old, while African-Americans had a slightly higher rate of abuse compared to 
whites, 1.3% to 0.5%, respectively (2).   
Currently, cocaine use remains a serious concern in the United States with an estimated 
1.5 million cocaine users age 12 and older (4) .  One study of US middle and high schoolers 
from 1991-1998 revealed a slight increased trend in cocaine abuse among study subjects over 
the study period (4).  Crack cocaine use also increased slightly, though not significantly, during 
the 1990s with roughly 500,000 crack users in 1994 compared to 604,000 users in 1997 (4). 
 
1.1.2 Crack Cocaine 
Crack cocaine is smokeable cocaine that derives its street name from the crackling 
sound heard when it is smoked (2).  It is the free-base form of cocaine hydrochloride, a fine, 
white crystalline powder that is primarily abused by other routes, intranasally and 
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intravenously (2).  Crack cocaine can be produced chemically from the hydrochloride salt by 
mixing with buffered ammonia, extracting with diethyl ether, and evaporating the organic 
solvent to produce crystals (2).  Another more popular method today of creating crack in 
clandestine laboratories is to heat cocaine hydrochloride with sodium bicarbonate until a solid 
rock forms (2).  Upon heating in a crack pipe or similar apparatus, the crystals liberate 
vaporized cocaine that is inhaled for pleasurable effects.   
The popularity of crack cocaine abuse can be attributed to numerous factors, such as 
rapid euphoric effects (typical high occurs in less than 10 seconds) due to fast absorption 
within the extensive capillary network in the lungs, and a relatively inexpensive street value 
($1-$3 per dose in 1996) (2).  Despite an overall variable and low bioavailability (32 to 77%), 
non-decomposed cocaine in aerosolized form is highly available in human test subjects (5).  
Cocaine free-base has a lower melting point than its hydrochloride counterpart (95°C and 
195°C, respectively), and the free-base is more volatile (3).  Smoking of drugs is advantageous 
over intravenous use since purity of the drug is less important and the lessened inherent 
dangers of acquiring pathogenic blood borne diseases, such as HIV (6).   
Overall, crack is a rapidly addicting form of cocaine that easily results in lethal 
overdose (3).  Unfortunately, some of the underlying factors for this increased toxicity are still 
unclear, but may be attributed to lesser-known pyrolysis products, such as anhydroecgonine, 
anhydroecgonine methyl ester, and anhydroecgonine ethyl ester. 
 
1.1.3 Cocaine Pharmacology  
The following brief overview of cocaine pharmacology may explain, in part, the 
euphorigenic properties of the drug.  Cocaine (Fig 1.1) is structurally similar to most local 
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anesthetics (i.e. lidocaine, procaine) with a tertiary amine structure derived from the amino-
alcohol base ecgonine, which is methylated and esterified with benzoic acid to form cocaine 
(benzoylmethylecgonine) (7).  Its overall tropane ring structure is similar to the potent 
muscarinic antagonist, atropine (Fig 1.1).  Pharmacologically, cocaine blocks the re-uptake of 
important neurotransmitters, norepinephrine locally and dopamine within the central nervous 
system (7).  Clinically, it provides nerve impulse blockade with concentrations as low as 
0.02%, leading to local anesthesia and vasoconstriction that is useful in certain clinical settings, 
such as nasal surgery (1).  However, the increased blockade of dopamine re-uptake leads to 
excitement, garrulousness and euphoria, a dreamy, pleasurable state sought by drug users.   
The intensity of euphoric effects from cocaine is faster and greater when cocaine is 
smoked or injected in comparison to intranasal use (8).  Smoked cocaine is readily absorbed 
through mucous membranes in the lung vasculature, reaching cerebral circulation within 6 to 8 
seconds (9).  By comparison, the intravenous route requires approximately 16 to 20 seconds to 
reach the cerebral vasculature, whereas nasal insufflation requires 3 to 5 minutes (9).  The 
bioavailability by the nasal route averaged 80% (5).  As previously mentioned, bioavailability 
after smoking cocaine varied (32-77%), but most undecomposed cocaine (ca. 44%) reaches the 
circulation unchanged (5).  In vitro simulated smoking experiments of a 50 mg free-base 
cocaine dose, inhaled at 30 second intervals over 5 minutes, showed that the first 4 puffs 
contained 94% of the cocaine delivered, and no cocaine was obtained after the 6th puff (10).  
Under optimal smoking conditions, smoking 50 mg free-base cocaine resulted in inhalation of 
approximately 16 mg cocaine (10).  Also, 16 mg of cocaine induced effects similar to or 
slightly more intense and pleasurable than 20 mg of IV cocaine HCl (10).  Overall, cocaine has 
pronounced, intense euphoric effects, yet they are ephemeral and rapidly dissipate, largely due 
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to the rapid hydrolysis of cocaine (short half-life) in vivo to primarily non-psychoactive 
metabolites.   
 
1.1.4 Cocaine Metabolism 
The metabolism of cocaine is extensively reviewed within the scientific literature and 
worthy of discussion in this proposal.  Cocaine is primarily biotransformed through hydrolysis 
of the methyl and benzoyl esters to produce benozylecgonine (BE) and ecgonine methyl ester 
(EME), respectively (Figure 1.2) (11).  Further hydrolysis of either moiety results in the 
formation of ecgonine (E) (11).  Interestingly, hydrolysis of cocaine to BE or EME is catalyzed 
by different human esterases.  Human carboxylesterase 1 (hCE-1), a microsomal serine 
hydrolase found in the liver, small intestine, kidney, lung, testes, heart and plasma, catalyzes 
the conversion of cocaine to BE (12).  Both human carboxylesterase 2 (hCE-2) and serum 
butyrylcholinesterase hydrolyze the benozyl ester linkage on cocaine to EME (12).  The non-
enzyme mediated chemical hydrolysis of either ester group also occurs at physiological pH 
(13). 
In the presence of ethanol, hCE-1 also catalyzes the transesterification reaction of 
cocaine to cocaethylene (CE), a toxic, pharmacologically active metabolite (12).  Traces of CE 
(ethyl cocaine) were reported in the urine of cocaine users who co-abused ethanol (14,15).  
Jatlow and co-workers (16) found, in 4 out of 7 human postmortem samples from victims who 
abused both cocaine and ethanol, a higher concentration of cocaethylene than cocaine.  Several 
studies state that cocaethylene is a more toxic compound than cocaine.  Cocaethylene exhibits 
similar affinity for the dopamine re-uptake transporter as cocaine (16,17).  The acute toxicity 
of cocaethylene was compared to cocaine in Swiss-Webster mice, and the LD50 of 
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cocaethylene was less than cocaine, 61 mg/kg and 64 mg/kg, respectively, suggesting it is more 
potent in inducing lethality (18).  Additionally, cocaethylene has a slower clearance and longer 
elimination half-life than cocaine (19).  Finally, the cocaine and alcohol combination can 
produce more intense feelings of high, and potentate the tendency towards violent thoughts 
and threats, which may result in an increase of violent behaviors (20)   
Cocaine is susceptible to other metabolic pathways in addition to hydrolysis and 
transesterification.  It is N-demethylated at the tertiary N-methyl group to produce norcocaine, 
a metabolite with similar pharmacologic activity as cocaine (11) and associated with cocaine 
related toxicities such as hepatotoxicity (21).  This N-demethylation is catalyzed by the 
cytochrome P450 isoenzyme, P450 3A, in humans and mice (21,22).  Norcocaine can be 
oxidized to N-hydroxynorcocaine by brain FAD-containing monooxygenases and further 
metabolized to norcocaine nitroxide by brain microsomes (23).  Additionally, norcocaine can 
be hydrolyzed to benzoylnorecgonine.  Cocaethylene is N-demethylated to norcocaethlylene or 
hydrolyzed to ecgonine ethyl ester (24).  Ester hydrolysis of norcocaethylene and ecgonine 
ethyl ester also proceeds non-enzymatically at physiological pH (24).  Cocaine or any other 
metabolite retaining the benzoyl functional group are theoretically subject to aromatic 
hydroxylation at the meta and para positions (25). 
 
1.1.5 Cocaine Addiction Therapeutics 
Approximately 16% of Americans have tried cocaine at least once, and 17% of those 
who try the drug will become addicted (26).  With a significant amount of U.S. citizens 
suffering from cocaine addiction, the National Institute of Drug Abuse (NIDA) is funding three 
different cocaine vaccine trials that aim to help cocaine users overcome their habit (27).  TA-
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CD therapeutic vaccine, currently in phase I clinical trials, is comprised of a protein conjugate 
that couples succinylnorcocaine to a carrier protein (recombinant cholera toxin B) with 
aluminum hydroxide as an adjuvant (28).  TA-CD (13, 82 or 709 µg) was well tolerated in 28 
test subjects and induced cocaine-specific antibodies, warranting further clinical studies (28).  
Other vaccines with slightly different modes of action are being pursued at Scripps Research 
Institute (La Jolla, CA) and at the University of Cincinnati (27).  Another vaccine being 
developed at Columbia University (New York) functions as a catalytic antibody (27).  The 
researchers have synthesized a phosphonate monoester transition-state analog for benzoyl 
esterolysis that selectively attacks circulating cocaine molecules, degrading them to the non-
toxic metabolites, benzoic acid and ecgonine methyl ester (29). 
Attacking cocaine (or any drug of abuse) addiction by synthesizing novel vaccines and 
related pharmaceutical agents, in the authors opinion, has more clinical promise than simply 
synthesizing a cocaine analogue that has a greater affinity for the dopamine transporter.  Still, 
many unanswered questions persist regarding the complexity of treating drug abuse, and 
additional data and research is needed to determine if these new therapeutic agents actively 
address the addiction.  
 
1.1.6 Pyrolysis of Other Drugs of Abuse 
 The formation of pyrolysis products during the smoking of drugs of abuse is not unique 
to cocaine.  Heroin (diacetylmorphine), phencyclidine (PCP) and methamphetamine (MA) are 
all heavily abused drugs in the US and susceptible to pyrolysis reactions during smoking 
(6,30,31).  The pyrolysate of heroin hydrochloride contained the following principal products 
on HPLC analysis:  6- acetylmorphine, N-acetylnorheroin, N,6-diacetylnormorphine and heroin 
 9
itself (6).  The tertiary benzylamine, PCP, undergoes an elimination reaction during pyrolysis 
to form primarily 1-phenylcyclohexene (PC) (32).  The newly formed double bond on PC, 
conjugated with the phenyl ring system, is oxidized to an epoxide, and then hydrolyzed to a 
diol (6).  The PC-epoxide may be a substrate for GSTs, and the resulting PC-SG adduct is 
potentially a novel metabolite of smoked PCP use.   
Methamphetamine, a CNS stimulant, mixed with tobacco produces a plethora of 
thermolytic products upon heating, such as phenylacetone, N-cyanomethylmethamphetamine, 
trans-β-methylstyrene, styrene, dimethylamphetamine and methamphetamine (30,31).  trans-1-
Phenyl-1-propene, a major thermal degradation product of methamphetamine hydrochloride, is 
a good substrate for CYP1A2, forming the epoxide, trans-1-phenylpropylene oxide (33).  The 
epoxide, also a substrate for cytosolic GSTs, is potentially a cytotoxic compound and forensic 
marker of smoked methamphetamine hydrochloride use (33).    
 
1.2.1 Anhydroecgonine Methyl Ester (AEME), a Pyrolysis Product of Cocaine 
Cook and Jeffcoat (32,34) first reported the thermal degradation of cocaine to 
methylecgonidine (AEME, andydroecgonine methyl ester).  Briefly, [N-CD3]-cocaine (25-200 
mg) was heated in a pyrolysis apparatus, and then the pyrolysis products were collected,  
dissolved in acetonitrile, and analyzed by GC/MS (34).  Also, the collected urine of a 
consented, test subject who inhaled about 50 mg free-base cocaine was compared to urine from 
test subjects administered the drug by intravenous or intranasal routes (34).  A greater 
proportion of unknown metabolites (likely AEME and derivatives) were discovered in the 
urine of smoked cocaine subjects (34).   
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Lowry (35) first identified methylecgonidine in the bile of a cocaine overdose patient.  
However, his discovery was likely an artifact for two primary reasons.  Firstly, the decedent 
reportedly abused cocaine intravenously, a route of administration not known to produce 
significant amounts of methylecgonidine.  Secondly, the investigators analyzed bile extractions 
from the patient using a GC/MS assay.  Toennes and co-workers recently reported that artifact 
AEME is formed by thermolytic breakdown of cocaine in the heated GC injector port (36).  
Furthermore, Lowry (35) reported a mass chromatogram of bile extract with a low intensity 
AEME peak (7%) roughly proportional to that observed from the thermal degradation of 
cocaine (37 µg/L in the bile) in the heated GC injector port (36,37).   Therefore, the earliest 
reports of the identification of AEME in humans following the suggestive NIDA report 
appeared in the literature during 1990 (38,39), and numerous studies thereafter (24,40,41).   
Typically, a cocaine user places a lump of crack on a screen in a pipe and heats the 
material while inhaling (42).  A significant rise in temperature causes cocaine to rapidly change 
state from solid to liquid to vapor (42).  Pyrolytic degradation of cocaine commences at 
temperatures greater than 170ºC (42).  For reference, the temperature of a glowing end of a 
tobacco cigarette reaches 800°C (34).  As the cocaine travels away from the flame and cools, 
smoke forms consisting of cocaine base droplets and pyrolysis products, primarily benzoic acid 
and AEME (42).  The vapor pressure of AEME is greater than cocaine free-base, so AEME 
coats the earlier condensing cocaine droplet during formation of the aerosol (42).  AEME is 
faster to evaporate, lingering around the crack smoking atmosphere longer than cocaine 
particles, suggesting that AEME may have forensic smoke and indoor air quality implications 
(42).   
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Determining a standard AEME amount formed during crack smoking is difficult due to 
variability in temperature and formation (43).  Cocaine is almost completely degraded at 800°C 
with only 16% of the pyrolysis product being intact cocaine (6).  One pyrolysis project 
indicated that 68% cocaine free-base was converted to AEME when heated to 320°C under 
vacuum, conditions not achieved in a crack pipe (44).  Another research group observed a 
maximum of 2% AEME formed after heating 10 mg cocaine free-base in a model crack pipe 
with a Bunsen burner at atmospheric pressure (42).  When 30 mg of free-base was heated to 
ignition, a maximum of 5% AEME was recovered (42).   
 
1.2.2 AEME Metabolism  
In specific forensic cases, AEME has been detected in the urine (38), blood/plasma 
(36), saliva/perspiration (40), hair (40), brain and liver (45) of crack cocaine users.  Although 
methylecgonidine has been identified in numerous matrices, fewer studies have reported its 
presence in blood or plasma samples (43).  The maximal urinary AEME concentration reported 
in the literature is 6.34 µg/mL while the maximum reported concentration in blood or plasma is 
0.11 µg/mL (43).  Part of the explanation on why AEME is detected in blood/plasma at lower 
concentrations than other matrices is due to its metabolism.   
The metabolism of AEME, in many ways, mirrors the metabolism of cocaine.  AEME 
is primarily metabolized by butyrylcholine esterase to a more polar entity, AE 
(anhydroecgonine), which has an average longer half-life than AEME (116 min vs. 20 min, 
respectively), and also a forensic marker of smoked cocaine use (43).  Although no studies 
have reported to date, AEME is likely a substrate for human carboxylesterase-1.  Similar to 
cocaine, the chemical hydrolysis of AEME proceeds more rapidly with increasing pH.  In one 
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study, AEME concentration was measured over time in phosphate buffer at pH 10 and 7.4 (46).  
After 7 days, the AEME concentration decreased by more than 96% at pH 10, while after 30 
days, the AEME concentration decreased only 50% at pH 7.4 (46). 
In addition to hydrolysis, AEME is oxidized to AEME N-oxide (AEMENO), a 
metabolic pathway also seen with cocaine and norcocaine (23).  AEMENO was detected by 
LC-MS after incubation of AEME (20 µg) with rat liver microsomes (47).  The N-oxide was 
also identified in the urine of known crack cocaine users (47).  The esterase-mediated 
transesterification of cocaine to cocaethylene in the presence of ethanol is well documented 
(48-50).  In fact, this transesterification reaction has been documented with several other 
pharmaceutical agents, including meperidine (51), methylphenidate (51-53), and acitretin 
(54,55) (Figure 1.3).  In rat liver microsomes, AEME (5 mM) was combined with ethanol (250 
mM), generating AEEE (anhydroecgonine ethyl ester, ethylecgonidine, EEG) (Figure 1.4) (56).  
This transesterification reaction was blocked by NaF (200 mM), a non-specific esterase 
inhibitor (56).   
In an analogous fashion to AEME, artifactual AEEE or AE may be generated in the 
heated GC injector port by the thermal breakup of cocaethylene or cocaine metabolites, 
confounding GC-MS analysis.  Recently, the artifactual production of AE from cocaine 
metabolites, benzoylecgonine, ecgonine or m-hydroxybenzoylecgonine, was reported, 
suggesting it is not a good marker for smoked cocaine use (37).  The identification of AEEE as 
a metabolite of cocaine and ethanol co-abuse has been suggested earlier by Isenschmid (57), 
but actual reports of AEEE in human subjects are non existent, to our recent knowledge, in 
peer-reviewed scientific reports.   
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1.2.3 AEME and AEEE Pharmacology 
AEME has unique pharmacological properties from cocaine in which it reportedly has 
no significant euphoric or reinforcing features in test subjects (58).  Containing a chemical 
structure (Fig 1.5) similar to the muscarinic agonists, arecoline and anatoxin A, AEME was 
originally hypothesized to exhibit cholinergic agonist activity (38).  Most later 
pharmacological studies on AEME reported results supporting this hypothesis (59-61).  In 
contrast, AEME was shown to relax airway smooth muscle in guinea pigs and antagonized 
bronchoconstriction induced by acetylcholine (58).  A recent, well-published report found that 
AEME acts as a muscarinic agonist in vivo when tested in awake sheep.  AEME administered 
intravenously (0.1-3.0 mg/kg) produced significant hypotension and tachycardia in sheep, and 
these effects were antagonized by pretreatment with the peripherally acting muscarinic 
antagonist, atropine methyl bromide (15 µg/kg) (43).  
 Pharmacological studies conflict on the chemical actions of AEMEs transesterification 
product, AEEE.  An intravenous dose of 3 mg AEEE was administered to rabbits, producing 
similar cardiovascular effects as AEME, such as hypotension and increased heart rate (60).  
Another study reported that AEEE exhibited only weak activity at muscarinic subtypes (m1-
m5) and showed no receptor selectivity (62).  The pharmacology of AE (ecgonidine), a 
hydrolysis product of AEME or AEEE, is currently unknown (43)  The exact role of cocaine 
pyrolysis products (AEME, AEEE, AE) in the sequelae of cocaine related toxicity continues to 
be studied. 
Chemically, AEME is an alkaline, bicyclic compound containing an electrophilic α,β-
unsaturated carbonyl moiety.  Based on previous literature reports of other compounds with a 
similar α,β-unsaturated carbonyl functional moiety, such as ethacrynic acid (63), arecoline 
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(64), methyl cinnamate (65) and morphinone (Fig 1.6) (66), AEME is susceptible to 
nucleophilic attack by thiol-containing compounds, like glutathione and cysteine.  The driving 
chemical reaction behind glutathione conjugation to such electrophilic compounds is a 1,4-
Michael addition reaction, also known as the Michael reaction. 
 
1.3 The Michael Reaction 
 In 1887 Arthur Michael reported that olefins conjugated with electron-withdrawing 
groups (Z) are susceptible to nucleophilic attack (67).  Although actually first reported by 
Claisen, Michael received widespread credit for the reaction known by his name, the Michael 
Reaction (68).  Structures of model Michael reaction acceptors include CH2=CH-Z, R-
CH=CH-Z (including quinones) and R-C≡C-Z (acetylenes) (67).  In general, the unsaturated 
compound in the Michael condensation is referred to as the acceptor (or electrophile), while the 
active hydrogen compound is the addendum (or nucleophile) (69).  The nucleophilic compound 
attacks the electrophilic compound to form a conjugate or adduct.   
 The demonstrated order of reactivity of olefins conjugated with electron withdrawing 
group (Z) with the standard nucleophiles (pyrrolidine or morpholine) is:  Z= CONR2 < CONH2 
< CO2R < CN < COR < CO < COAr < NO2 (67).  Reactions were followed to at least 75% 
completion and overall, were second order (first order in each of the reactants) (67).  For 
instance, at 30°C, morpholine (80M) reacted with methyl acrylate (100M; Z=COOCH3) to 
produce a 2nd order rate constant of 103 L/mol⋅sec , whereas the reaction of morpholine (0.128 
M) with acrolein (0.128M; Z=CHO) or methyl vinyl ketone (0.128M; Z=COCH3) produced 
larger rate constants of 11,360 and 13,000, respectively (67).   
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 We speculate that the acrolein or methyl vinyl ketone conjugate carbanion, formed after 
nucleophile addition, is more stable than the methyl acrylate carbanion counterpart, leading to 
greater product generation.  Greater stabilization of a carbanion bearing an aldehyde or ketone 
substituent versus a methyl ester group was documented previously (70).  Additionally, the 
methyl vinyl ketone conjugate anion, versus the acrolein conjugate anion, demonstrates 
possible enhanced stabilization due to polarization by the additional methyl group (71).      
Michael reactions are reversible, regenerating the original olefin, by the same alkaline 
catalyst that favors condensation (72).  In general, lower temperatures favor condensation 
while elevated temperatures increase retrogression (72).  Preferably, the in vitro reaction is 
carried out for only several hours, as increased reaction time re-generates greater 
concentrations of the original reactants (LeRoy Salerni, Ph.D., Butler University; unpublished 
data).  The retro-Michael reaction can be retarded, in part, by using an excess of one of the 
reactants, causing a shift in equilibrium towards conjugate formation (72).  Retrogression is 
more likely to occur when the condensation is slow (72).  One of the factors that slows 
condensation is the presence of a large number of substituents at the α,β double bond (72).   
For example, the reaction rate at room temperature for pyrrolidine (80M) mixed with 
acrylamide (100 M; Z= CONH2) is 83.5 L/mol⋅sec, while the reaction is markedly decreased 
(0.541) with p-nitrostyrene [100 M; Z=C6H4⋅NO2-p] (67).   
A competing 1,2-addition (to the C=O or C≡N) sometimes predominates over the 1,4-
addition (73).  However, the 1,2-addition mainly occurs in aldehydes (73).  In addition, 1,2-
adducts are often substantially less stable than the 1,4 adducts, and if the Z group (from the 
electrophile) is not a sufficiently good leaving group, the initial 1,2-adducts can reform the 
starting nucleophile and acceptor (74). 
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The Michael Reaction shows stereospecificity.  When the substrate contains suitably 
different R groups, two new chiral centers are generated (73).  The product, therefore, can exist 
as two pairs of enantiomers (73).  In a distereoselective process one of the two pairs is 
predominantly formed as a racemic mixture (73).  Many examples have been reported in the 
literature (74).  In this research project, the stereochemistry following nucleophile addition to 
AEME is partially elucidated. 
 A key player in a biologically occurring Michael reaction is the cellular nucleophile, 
glutathione (GSH), which is reviewed next. 
 
1.4 Glutathione (GSH) Conjugation     
GSH was initially called philothion and was first isolated in 1888, but its structure 
was elucidated 40 years later (75).  GSH is a ubiquitous tripeptide (L-γ-glutamyl-L-
cysteinylglycine) that is usually the most prevalent intracellular thiol (76).  The intracellular 
concentrations of GSH range between 0.1-10 mM and varies among tissues (76).  Regarding 
tissue distribution, the highest concentrations of GSH are found in the liver, spleen and kidneys 
while lower concentrations are present among the heart, lungs and blood (77).  GSH is 
oxidized at the thiol group of the cysteine residue to the disulfide product, GSSG, which was 
measured at 10-15% of the total GSH concentration in rat blood plasma (78).  Interestingly, 
this oxidation reaction is more active in rat kidney cells in comparison to rat liver cells (78). 
GSH functions directly or indirectly in many important biological processes, including 
the synthesis of proteins and DNA, transport, enzyme activity, metabolism and protection of 
cells (78).  The GSH function pertinent to this discussion involves the conjugation of the 
nucleophilic thiol-group of GSH to electrophilic xenobiotics, precluding the toxic reaction of 
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these substances, in most cases, with biological macromolecules (75).  For example, the 
commonly used analgesic agent acetaminophen (Tylenol) is enzymatically N-oxidized to a 
reactive, electrophilic quinoneimine metabolite (NAPQI), which reacts with GSH to form a 
less toxic glutathione conjugate (79).  At therapeutic doses, acetaminophen is non-toxic to 
normally functioning livers, but in excessive doses it causes severe liver necrosis, arising from 
metabolite induced glutathione depletion that allows the reactive quinone to covalently bind 
macromolecules in the liver (79). 
In less common instances, glutathione conjugation can lead to the formation of a 
bioactive substance (75).  Ethacrynic acid, a loop diuretic, reacts with GSH to form an 
ethacrynic acid-SG adduct, which was found to be a potent inhibitor of rat and human 
glutathione-S-transferases (80,81).  Other chemicals biotransformed to bioactive GSH-
conjugates include dihalomethanes and isocyanates (75).  For example, the GSH conjugation 
of the dihaloalkane, dichloromethane, initially yields  S-chloromethyl-GSH (82).  This 
intermediate is converted nonenzymatically to S-hydroxymethyl-GSH (a hemimercaptal of 
formaldehyde and GSH), which eliminates formaldehyde and glutathione (82).  
Dichloromethane-GSH metabolism has been linked to the development of tumors in animals 
(82). 
Some thiol adducts of α,β-unsaturated aldehydes, such as 1:2 crotonaldehyde-cysteine, 
exhibit biologic activity similar to the parent chemical (75).  One explanation for this 
phenomenon suggests that the retro reaction leads to adduct dissociation at the target site and 
regeneration of the toxic, parent compound (83).  Another study demonstrated that the reaction 
of 4-hydroxy-pentenal with sulfhydryl groups of proteins is reversible by an excess of GSH or 
other protein thiol groups (84).  Using ethacrynic acid (EA), Ploemen and co-workers (85) 
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studied the retro Michael cleavage of the EA-SG conjugate by the addition of an excess of N-
acetylcysteine or the enzyme GST P1-1 (pi).  Their findings suggest that EA may be 
transferred from one low molecular weight compound to another or to a reactive cysteine in 
proteins, such as cysteine 47 of GST P1-1 (85). 
 
1.5 The Mercapturic Acid Pathway 
 The mercapturic acid pathway is a multi-step enzyme-mediated process that initially 
forms a glutathione adduct and then prepares it for elimination in the body (Fig 1.7).  Several 
of the significant steps will be reviewed here. 
 
1.5.1 Glutathione S-Transferases (GSTs) 
 GSH conjugation to xenobiotics is the first step in the mercapturic acid pathway.  In 
1960, researchers first concluded that GSH conjugation is catalyzed by rat liver cytosol (86).  
During the mid 1970s, four different glutathione transferases were isolated from rat liver 
cytosol (75).  These enzymes, which have evolved together with GSH in aerobic organisms, 
are abundant and widely distributed in most forms of life (87).  Today, there are currently eight 
identified human soluble/cytosolic glutathione S-transferase (GST) isoforms that comprise the 
major GST supergene family (88):  alpha (A), mu (M), theta (T), pi (P), zeta (Z), sigma (S), 
kappa (K), and omega (O).  Kappa GST, although soluble, is mitochondrial and not found in 
the cytoplasm (89).  Allelic variants have been discovered in all of the isoforms except kappa, 
sigma and omega (88).  The other superfamily of GSTs are microsomal proteins termed 
MAPEG and primarily involved in the metabolism of arachidonic acid (89).   
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Overall, the GST family of isoenzymes represent around 1% of total cellular protein 
(90).  In the human liver, the cytosolic GSTs are more concentrated and comprise on average 
about 4-5% of total cytosolic protein (91,92).  In general, different organs express different 
concentrations of soluble GST isoforms (89).  For instance, the kidneys express alpha, pi, mu, 
theta and omega isoforms, the lungs contain predominantly pi, and the developed liver 
expresses alpha, kappa, mu, theta and omega (89).  Many tumor cells over express total 
cytosolic GST activity, leading to resistance of chemotherapeutic drugs by chemical 
detoxification through elevated GSH conjugation (93).  Several reports have found total 
cytosolic protein concentration ranging from 4-40 µg of GST/mg of cytosolic protein in tumors 
and tumor cell lines (93).  Potent inhibitors of GSTs, such as ethacrynic acid, have been 
utilized in clinical studies to potentially enhance the cytotoxic effects of anti-tumor drug 
regimens (90).             
Although they may serve as intracellular carrier proteins for ligand transport (87), the 
GSTs primarily catalyze conjugation reactions toward a diverse range of substrates (i.e. 
epoxides, lactones, quinones and esters) that are potentially hazardous to cells (92).  Substrates 
share, however, the common feature of being mostly hydrophobic and bearing an electrophilic 
center (92).  Each cytosolic enzyme has two active sites per dimer that behave independently 
of each other (92).  The active site contains at least two binding regions:  specific hydrophilic 
GSH binding site (G site) and less specific hydrophobic substrate binding site (H site) (92).  
Interestingly, a tyrosine residue within the active site is one of the few known residues 
conserved among the known GST sequences, suggesting an important role in the catalytic 
mechanism (92).  Current understanding of the mechanism by one author implies that the 
thiolate anion of enzyme-bound GSH is stabilized at neutral pH through hydrogen bonding 
 20
with the hydroxyl group of the tyrosine residue (75).  On the other hand, another hypothesis 
suggests that a basic amino acid residue, such as arginine or histidine, converts GSH to the 
active SG moiety (94).  Site-directed mutagenesis studies revealed that replacement of 
arginine residues in GST-α with other amino acids results in decreased activity (94).  
 
1.5.2 Metabolism of GSH Conjugates 
GSH conjugates, whether enzymatically or non-enzymatically formed, are rarely 
excreted unchanged in the urine since they contain a high molecular weight and amphiphilic 
structure (79).  Although they can be eliminated in the bile, most conjugates are metabolized 
further to mercapturic acid derivatives for elimination in the urine.  The first step in the 
catabolism of GSH-conjugates is mediated by the enzyme, γ-glutamyltransferase (GGT), which 
hydrolyzes or transfers the γ-glutamyl group to an appropriate receptor (75).  GGT is a 
ubiquitous enzyme present in serum and all cells except muscle cells (95).   
The products of GGT catalysis, cysteinylglycine S-conjugates, are degraded to cysteine 
S-conjugates by the enzymes, cysteinylglycine dipeptidase (dipeptidase) or aminopeptidase-M 
(75).  Dipeptidase is a zinc metalloproteinase which has been identified in the kidneys of 
humans (96).  Aminopeptidase-M is also a zinc-containing metallopeptidase and is widely 
distributed in mammalian tissue within the central nervous system, kidney and intestinal 
microvilli (75).  Although aminopeptidase-M is more abundant than cysteinylglycine 
dipeptidase, dipeptidase plays a larger role in the metabolism of GSH conjugates (75).   
Cysteine S-conjugates are N-acetylated by cysteine S-conjugate N-acetyltransferase to 
N-acetylcysteine derivatives, also termed mercapturic acid derivatives or mercapturates (75).  
This acetyltransferase has been isolated from rat kidney microsomes and appears to function 
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within the proximal renal tubule cells (97).  Additional metabolic pathways of GSH conjugates 
not discussed within this review in more depth include oxidation and cleavage of cysteine-S-
conjugates followed by glucoronidation, sulfation or methylation (75). 
 
1.5.3 GSH Conjugate Transport 
Transport of GSH conjugates out of the cell is a critically important cellular function 
since accumulation of conjugates within the cell can lead to inhibition of GSTs and GSH 
reductase (98).  There are at least three different transport systems with different substrate and 
transport characteristics (75).  The GS-X pump, or multi-specific organic anion transporter, is 
ATP-dependent and distributed among different organs and cell types in the body (98).  The 
diverse range of substrates for the GS-X pump includes metabolites of anticancer drugs, 
glucuronide conjugates, sulfate conjugates, leukotrienes and prostaglandins (98).  
Another transport system is Na+-dependent and transports GSH, GSH conjugates,  
γ-glutamyl derivatives and probenecid (75).  This system is found in the basolateral membranes 
of the kidneys and intestine (75).  The third transport system is Na+ -independent and found in 
the brush borders of intestinal cells and liver cells (75).  It may exchange GSH conjugates or 
organic anions with GSH (75).  Catabolites of GSH conjugates are possibly transported by 
carriers that also transport amino acids and dipeptides (75).  Well known organic anion 






1.6 Examples of Michael Acceptors in the Literature 
The pharmaceutical science literature is crowded with numerous examples of drugs and 
metabolites that conjugate with GSH.  For this discussion, three pertinent compounds are 
reviewed:  morphinone, arecoline and ethacrynic acid (Fig 1.6).   
 
1.6.1 Morphinone 
Morphinone (MO), containing an α,β-unsaturated ketone, is the oxidation product of 
the opiate analgesic morphine in the presence of morphine dehydrogenase (66).  MO reacts 
readily with the thiol containing compounds 2-mercaptoethanol, cysteine and glutathione by a 
1,4 Michael addition reaction (99).  The in vitro reaction of MO with GSH obeyed second 
order kinetics (k = 13.5 Lmole-1min-1) while the reaction with cysteine was too rapid to 
determine the rate constant (99).  Ishida and co-workers (66) synthesized and purified an 
authentic MO-GSH adduct for analytical comparison to the MO-GSH metabolite extracted 
from test animals.  Briefly, morphine (25 mg/kg) and GSH (100 mg/kg) were injected at 
different sites into guinea pigs and the bile was subsequently collected for 8 hours (66).  MO-
GSH was purified from the bile after extensive chromatography, and the structure of the 
metabolite was analyzed by FABMS (MH+ = 591) and NMR spectrometry.  Interestingly, two-
dimensional NMR spectrometry (COSY and HETCOR) confirmed that the GSH residue 
preferentially attacks C-8 from the upper (less sterically hindered) side of the molecule, 
forming the 8S isomer (66).  A similar stereochemical picture is observed with the related 
metabolite codeinone-GSH, an oxidation product of codeine, which has been detected in the 
bile of codeine-treated guinea pigs (100).     
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An extension of these studies measured the enzymatic rate of GSH conjugation to MO 
(101).  Enzymatic formation of MO-GSH was determined in an incubation mixture containing 
1 mM MO, 1 mM GSH, enzyme (0.5 mg protein purified on a Sephadex G-25 column from the 
cytosol of guinea pig liver), and 0.1 M sodium phosphate buffer (pH 6.5) to a final solution 
volume of 2 mL (101).  Reactions were carried at 25°C for 2 minutes.  MO-GSH was formed 
in both native and boiled cytosol preparations containing MO and GSH (101).  Interestingly, 
the enzymatic rate proceeds at an optimum pH of 6.0, whereas the non-enzymatic rate 
increases with increasing pH (101).  In addition, the enzymatic reaction was greater at lower 
concentrations of GSH, with an optimal rate achieved with 1 mM GSH (101).  This 
observation of enhanced rate at lower GSH concentrations has also been reported with GSH 
addition to the acetaminophen metabolite, NAPQI (102). 
   
1.6.2 Arecoline 
Arecoline (arecaidine methyl ester) is the major alkaloid of betel nuts, fruits of Areca 
catechu, a tall palm cultivated in India, southestern Asia, the East Indies and East Africa (103).  
A common masticatory mixture (betel) composed of the nut, shell lime and leaves of Piper 
betle (a climbing species of pepper) is chewed to release euphoretic chemicals (104).  Natives 
of India and the East Indies have consumed this mixture for its stimulatory properties since 
antiquity (104).  Arecoline has been used therapeutically in veterinary medicine as a vermicide 
and taeniacide (104).  Pharmacologically, it binds to muscarinic and nicotinic receptors (104). 
Currently, there are an estimated 600 million betel quid (BQ) chewers in the world, and 
BQ chewing is a major etiologic factor of oral cancer (105).  Briefly, arecoline was found to 
deplete cellular glutathione levels, one of several key factors leading to the disruption of the 
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normal cell cycle control of oral mucosal fibroblasts and keratinocytes (105).  Boyland and co-
workers (64) were among the first researchers to show that arecoline is hydrolyzed to 
arecaidine in rats, and both substances are eventually converted to mercapturic acid 
derivatives.  Arecoline (12.5 nM) or arecaidine (12.5 nM) plus GSH (5 nM) when incubated 
for 40 minutes, with or without liver preparations, (mouse, rat, hamster, duck or whole rat) at 
pH 6.8, formed the corresponding GSH conjugate (64).  However, the presence of liver 
preparations did not affect the rate of reaction (64).   
Another study reported that arecoline 20 and 40 mg/kg administered intraperitoneally to 
swiss albino mice of either sex for 10 or 30 days significantly enhanced cystosolic GST 
activity in both sexes at 10 and 30 days (106).  In addition, arecoline 40 mg/kg significantly 
reduced acid soluble sulfhydryl content in liver tissue in both sexes after 10 and 30 days (106).  
But a later study from a different research group showed that arecoline (25-200 µg/mL) 
incubated for 24 hours with human buccal mucosal fibroblasts significantly reduced GST 
activity towards the common GST substrate, CDNB (1-chloro-2,4-dinitrobenzene), at all tested 
arecoline concentrations (107).  Changs study suggests that arecoline is a GST inhibitor (107).     
 
1.6.3 Ethacrynic Acid (EA) 
 EA (Fig 1.6) is a potent, short-acting loop diuretic that inhibits the Na+-K+-2Cl- 
symport in the thick ascending limb of the loop of Henle within the renal tubules (108).  
Chemically, it is a phenoxyacetic acid derivative that contains a reactive electrophilic α,β-
unsaturated ketone moiety.  In one of the earliest reports on the metabolism of ethacrynic acid, 
35S-GSH was administered intravenously to rats one hour before 14C-EA at a dose of 5 or 50 
mg/kg (63).  The radioactive EA-GSH adduct was identified in the bile within 10 minutes 
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following administration (63).  After 30 minutes, the major metabolite identified in the bile 
was the EA-mercapturate (63). 
 The chemical synthesis of the EA-SG adduct resulted in approximately equal amounts 
(46:54) of diastereoisomers (R or S about C-9) based on NMR analysis (109).  GSTP1-1 (pi), 
mutant GSTP1-1 (C47S) and GSTA1-1 (alpha) all stereospecifically catalyze the formation of 
one of the diastereomers, whereas GSTA1-2 and GSTA2-2 showed no stereospecificity (109).  
Three-dimensional crystal structures of GSTA1-1 and GSTP1-1 in complex with an EA-SG 
diastereoisomer are deposited in the Brookhaven PDB databank (109).  Interestingly, the PDB 
file of the complexed GSTA1-1 shows the R-isomer, while the GSTP1-1 complex PDB file 
contains the S-file (109).  Currently, the correct diastereometric structure (R or S about C-9) of 
the enzyme catalyzed product is unknown. 
EA is a potent reversible inhibitor of rat and human glutathione S-transferases with 
reported I50 (µM) values for alpha, mu and pi class GSTs of 4.6-6.0, 0.3-1.9 and 3.3-4.8, 
respectively (81).  The EA-SG conjugate displayed a stronger inhibition for alpha and mu 
GSTs with I50 (µM) values around 0.8-2.8 and 0.1-1.2, respectively (81).  The conjugate, 
however, showed a weaker inhibition of the pi class with a measured inhibitory value of  
11.3 µM (81).  EA also inhibits rat and human pi-class GSTs through covalent binding to a 
cysteine residue on the enzyme (81).  Time course labeling of GST pi was followed by 
incubating 14C-EA (6.25 µM) with 1.25 µM enzyme, resulting in 65-93% inhibition of GST 
catalytic activity towards CDNB (81).  GST pi class isoforms (1µM) inactivated by 10 µM EA 
(> 90% loss) regained full catalytic activity by incubation with an excess of glutathione  
(1 mM) over 125 hours (81).                         
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 Finally, one study compared the rates of formation of the EA-SG adduct in enzymatic 
and non-enzymatic preparations (110).  EA (4 mM) was incubated at 25°C with GSH (2.5 
mM) in phosphate buffer (pH 6.0, 6.5 and 7) with or without GST-π  (22 µg/mL) (110).  Small 
aliquots (100 µL) were analyzed by injection onto a HPLC column over various time intervals 
from 1 to 150 minutes (110).  Enzyme accelerated the initial rate of EA-SG formation by 
approximately 2.8 and 1.1 fold at pH 6.5 and 7.4, respectively (110).  Initially, the 
enzymatically mediated reaction was faster for 10 minutes, but the two rates were comparable 
thereafter until the final time point of 150 minutes (110).  In addition, the non-enzymatic rate 
showed a positive correlation with increasing pH, as an approximately 2.5 fold greater rate was 





































































































Figure 1.3:  Chemical structures of pharmacologic agents that undergo transesterification (or 




































Figure 1.4:  Schematic showing the transesterification of cocaine to cocaethylene and AEME 





















































Figure 1.6:  Chemical structures of compounds containing an α,β-unsaturated carbonyl 





























































Figure 1.7:  Overview of the mercapturic acid pathway.  E+ represents a generic substitution for an 
electrophilic agent. 
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1.7 Research Objectives 
 Since smoking free-base cocaine results in the formation of electrophilic, potentially 
reactive compounds, these toxic metabolites may play a role in cocaine associated toxicity.  In 
addition, some of these metabolites may be additional human markers of smoked cocaine use.  
The main research objectives are the following: 
 
1.  To synthesize mercapturic acid and glutathione conjugates of arecoline and related 
     derivatives. 
2.  To synthesize mercapturic acid and glutathione adducts of AEME and related  
     compounds. 
3.  To analyze the stereochemistry of the AEME mercapturate (C-2 and C-3) following NAC 
     addition to AEME. 
4.  To investigate the chemical kinetics of glutathione addition to AEME and other known 
     Michael acceptor compounds. 
5.  To demonstrate the reduction of chemically generated DCNB-SG conjugate in the 
     presence of AEME, arecoline or EA. 
6.  To monitor the degradation of selected glutathione conjugates over time at physiological  
     pH. 
7.  To determine if AEME is a substrate for cytosolic glutathione S-transferases contained  
     within pooled human liver cytosol. 
8.  To establish if AEME inhibits cytosolic GST activity. 
9.  To quantify the relative concentration of AEEE in a urine sample from a known 
     cocaine/ethanol abuser. 
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10.  To identify AEME-NAC in a urine sample from a known free-base cocaine user. 
11.  To assess the cytotoxicity of AEME, AEEE, AE and cocaine against A549 lung fibroblasts 















2.1 Materials and Methods 
 
Chemicals:  Anhydroecgonine methyl ester and anhydroecgonine HCl were purchased from 
Cerilliant Corp. (Austin, TX) and used in earlier synthetic and analytical studies.  AEME 
fumarate was graciously supplied by F. Ivy Carroll, Ph.D. (National Institute on Drug Abuse, 
Division of Neuroscience and Behavioral Research, Research Triangle Park, NC) and used in 
some synthetic procedures.  Glutathione (GSH), NAC (N-acetylcysteine), DTNB ((5,5'-dithio-
bis (2-nitrobenzoic acid)); Ellmans reagent), DCNB (3,4-dichloronitrobenzene), CDNB (1-
chloro-2,4-dinitrobenzene), THAM® (tris-hydroxymethyl aminomethane), ammonium acetate, 
potassium phosphate, potassium carbonate, sodium bicarbonate, sodium sulfate, cocaine HCl, 
fumaric acid, arecoline HBr, DMSO (dimethyl sulfoxide), DMSO-d6, CD3OD, CD3Cl, and 
D2O were all purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO).  A 5 mM solution 
of Ellmans reagent in phosphate buffer (pH 7.4) was prepared for UV analysis.   
 Methanol, chloroform, acetonitrile, benzene, diethyl ether, acetone, 1-propanol, 2-
propanol, methylene chloride, ammonium hydroxide (21%), glacial acetic acid and sulfuric 
acid were obtained from Fisher Co. (Pittsburgh, PA).  Concentrated HCl (37%) was obtained 
from Acros Organics (New Jersey, USA).  Absolute ethyl alcohol (200 proof) was obtained 
from Aaper Chemical Co. (Shelbyville, KY).  Distilled water was generated from a Barnstead  
Nanopure system (Dubuque, IA).   
 HPLC grade solvents were used for HPLC analyses, laboratory or HPLC grade solvents 
were utilized for synthetic procedures, and optima grade solvents were used for MS, LC-MS, 
LC-MS/MS analyses.  SPE elution mixture consisted of optima grade solvents and optima 
grade ammonium hydroxide. 
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   Pooled human liver cytosol (20 mg/mL protein content) and single donor human liver 
cytosol (HK27; 20 mg/mL) were obtained from Gentest (BD Biosciences; Woburn, MA) and 
stored at -80°C until use.  A549 lung fibroblast cells were obtained from the American Type 
Culture Collection (ATCC; Manassa, VA).  Hanks Balanced Salt Solution was purchased 
from Mediatech, Inc. (Herndon, VA).  Kaughns modification of F12 (HyQ Hams/F-12 media 
containing 1.00 mM L-glutamine) and trypsin containing 0.25% EDTA were purchased from 
Hyclone (Logan, Utah).  Trypan blue (0.4% in PBS) was purchased from Mediatech, Inc. 
(Herndon, VA).  Propidium iodide (PI) was purchased from Sigma-Aldrich (St. Louis, MO).  
A549 cells, salt solution, media, trypsin/EDTA, trypan blue and PI were generously donated 
from the laboratory of Slawomir Lukomski, Ph.D. (Deparment of Microbiology, Immunology 
and Cell Biology, West Virginia University).   
 
Urine Samples:  Urine samples collected from several multiple drug overdose/suicide victims 
at the Office of the Chief Medical Examiner (OCME) in Charleston, WV were stored at -80°C 
in a vacuum-sealed container until future use.  Urine samples were completely thawed before 
use by placing in a laminar airflow hood (Labconco; Kansas City, MO) at room temperature 
for several hours. 
 
Instrumentation:  All melting points were determined on a Thomas-Hoover melting point 
apparatus.  Samples were evaporated to dryness using solely or a combination of the following 
systems:  Rotavapor-R (Büchi, Flawil, Switzerland) rotavap system connected to a vacuum 
pump (Duo Seal, General Electric); Savant Speed Vac SVC 100 (GMI; Ramsey, MN); or 
standard vacuum dessicator connected to a vacuum pump.  Incubations were conducted at 
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37°C in a Precision (Winchester, VA) shaking water bath incubator.  Experiments measuring 
UV/VIS absorbance of analytes utilized a Beckman DU 640 spectrophotometer (Beckman 
Coulter; Fullerton, CA).  NMR data was recorded on a Varian Gemini 2000, 300 MHz 
broadband spectrometer or Varian Inova 600 spectrometer (Varian; Palo Alto, CA). 
 GC-MS analysis of the metabolites was conducted on an Agilent (Palo Alto, CA) 5973 
Electron-Impact gas chromatograph/ mass spectrometer.  Samples were analyzed on a Supelco 
Equity 1 (St. Louis, MO) capillary column with an oven temperature of 90°C held for 1 minute 
and then programmed at 20°C/min to 280°C, with a total run time of 12.50 minutes.  Helium 
was the carrier gas, and the injection volume was 2 µL per injection. 
One LC-MS system was as follows.  Reversed phase LC analysis of compounds was 
performed with a Waters 2695 (Milford, MA) separation module and a Waters 996 Photodiode 
Array Detector with UV scanning from 200 to 400 nm.  This HPLC system was coupled to a 
Waters Micromass ZMD mass spectrometer programmed to utilize electrospray ionization in a 
positive ion mode.  Source conditions:  capillary 3.35 kV; sample cone 20 V; extraction cone 8 
V; source block temperature of 100°C and desolvation gas temperature of 300°C; and 
desolvation gas flow and cone gas flow (both N2) were 250 L/hr and 95 L/hr, respectively.   
A stand-alone LC system (Waters) similar to the HPLC described above was utilized in 
some experiments.  Types and conditions of analytical columns and solvent systems will be 
described in more detail under the experiments to follow.   
Multistage mass spectrometry LC-MS/MS:  Shimadzu (Columbia, MD) LC-10ADvp 
LC system (equipped with a SPD-10A UV/VIS detector, SIL-10ADvp auto injector and DGU-
14A degasser) coupled to a Thermoquest LCQ DECA (San Jose, CA) ion trap mass 
spectrometer was used for MS, MS/MS and MS3 analyses.  The electrospray source (ESI) 
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included:  positive ion detection; sheath N2 gas flow rate 80 (arbitrary units); spray voltage 2.5 
kV; capillary temperature 240°C; capillary voltage 7.00 V; and tube lens offset 15.0 V. 
The microscope used for determining cell viability was an Axiostar Plus microscope 
(Zeiss; Thornwood, NY) with an AxioCam for capturing cell images.  Flow cytometry was 
performed with a FACSCalibur (Becton Dickinson; Franklin Lakes, NJ) flow cytometer with a 
15 milliwatt 488 nm argon laser; and it was operated by Dr. Cynthia Cunningham of the Flow 
Cytometry Core Facility at WVU.    
 
2.1.1 Synthesis of 4-(N-Acetylcystein-S-yl)Arecoline 
 The synthesis of the arecoline mercapturic acid (arecoline-NAC) was modified from a 
previously reported method (64).  Arecoline hydrobromide was dissolved in 15.0 mL distilled 
water, alkalinized with K2CO3 (ca. 4 g) to pH 10.0, extracted several times with methylene 
chloride (50 mL), and dried for 20 minutes over sodium sulfate.  The combined, dried organic 
layers were vacuum filtered and evaporated in vacuo to a yellowish oil containing arecoline 
free-base.  Arecoline free-base (0.619 g, 3.99 mmole) was combined with N-acetylcysteine 
(NAC; 4.14 mmole) and dissolved in 25 mL absolute ethanol.  The solution was stirred for 3 
hours at room temperature under N2 and then evaporated to dryness.  The gummy clear residue 
was dissolved in 15 mL warm ethanol, cooled to below room temperature, and precipitated by 
the dropwise addition of diethyl ether.  The white precipitate was dissolved in a minimal 
amount of warm 1-propanol, transferred to a sublimation apparatus, reduced to dryness, and 
sublimed under reduced pressure to yield soft, white crystals:  yield= 44%; m.p. 115-120°C; 
ESI-MS (MH+= 319, MS/MS= 190, 156, MS3 of 190 = 156; 1H NMR spectrometry (DMSO-
d6):  disappearance of the olefinic proton (H-4) at 7.01 ppm. 
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 2.1.2 Synthesis of 4-(Glutathion-S-yl)Arecoline 
The synthesis of the arecoline-SG conjugate was modified from the aforementioned 
synthesis of the arecoline mercapturate.  Briefly, arecoline HBr (0.5 g) was alkalinized, 
extracted into organic phase, dried over sodium sulfate and the volatile components evaporated 
in vacuo.  Arecoline free-base (240 mg, 1.55 mmole) was combined with reduced glutathione 
(1.7 mmole) and dissolved in 30 mL of 50% ethanol.  The solution was stirred under N2 for 4 
hours at room temperature, and then extracted twice with diethyl ether (40 mL).  The combined 
aqueous layers were concentrated under vacuum and dried under reduced pressure.  The soft, 
glassy residue was precipitated from a water/acetone mixture.  Arecoline-SG was analyzed as 
follows:  m.p. 160-165°C; ESI-MS (MH+= 464; MS/MS= 335; MS3 of 335= 302, 190, 188, 
156); one single spot on TLC (Rf = 0.42 on SiO2 plates eluting with propanol/10% ammonium 
hydroxide 67:33; developed under iodine vapor); HPLC (tR = 3.05 minutes using a mobile 
phase of methanol/water (70:30), at 1.0 mL/min, UV detection at λ= 215 nm, separated by a 
Phenomenex Bondclone C18, 10µ, 300x3.90 mm analytical column). 
 
2.1.3 Synthesis of Arecaidine Propyl Ester 
 Arecaidine propyl ester (Fig. 1.5) was initially proposed as an internal standard for 
future experiments.  Even though those experiments were not conducted, this synthesis was 
useful as a practice method for the synthesis of AEME from cocaine.  Here, the brief details of 
this synthesis follow.  Arecoline HBr was converted to its free-base (588 mg, 3.79 mmole), 
dissolved in 20 mL of 6M HCl solution and refluxed at 110°C for 17 hours.  Following 
refluxing, the mixture was evaporated to dryness as a white powder and precipitated from a 
combination of 80% ethanol and diethyl ether.  The precipitate was stored at 0°C overnight, 
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vacuum filtered and dried further under vacuum to a fine, white powder.  Arecaidine (1.7 
mmole) was dissolved in 20 mL 1-propanol and 0.4 mL concentrated HCl and refluxed 
overnight.  The resultant solution was cooled to room temperature, evaporated under vacuum 
to a yellowish, gummy oil and dried further in a dessicator:  yield= 94%;  m.p. 129-131°C; 
ESI-MS (MH+= 142; MS/MS= 123, 105, 96); one single spot on TLC (Rf= 0.800 eluting on 
silica plates using a solvent system consisting of chloroform:methanol:ammonium hydroxide, 
80:18:2). 
 
2.1.4 Synthesis of 4-(Glutathion-S-yl)Arecaidine Propyl Ester   
 Briefly, arecaidine propyl ester HCl (10 mg, 54.6 µmole) and reduced glutathione (34 
mg, 110 µmole) were dissolved in 1 mL ammonium acetate buffer (0.1 M, pH= 7.4) and stirred 
under N2 at room temperature for 3 hours.  The resultant mixture was evaporated in vacuo 
overnight, precipitated in warm 1-propanol and further cooled at 0°C overnight.  The product 
was analyzed by ESI-MS (MH+= 492; MS/MS= 363; MS3 of 363= 184, 216, 303). 
 
2.2.1 Synthesis of Anhydroecgonine Methyl Ester (AEME) 
 AE and AEME were synthesized by a modification of several literature methods (111-
113).   
Anhydroecgonine (AE):  670 mg cocaine HCl (1.97 mmol) was dissolved in 15 mL 
concentrated HCl and refluxed under N2 at 110°C for 24 hours.  After cooling, the aqueous 
solution was extracted thrice with ethyl ether (30 mL) to remove benzoic acid.  The resulting 
aqueous layer was evaporated in vacuo and the resultant residue was dried by azeotroping with 
toluene (30 mL).  A mixture (60:40) of anhydroecgonine hydrochloride was obtained by 
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precipitation of the residue from an acetone/water mixture.  Product (1.0 g, 5.3 mmole) had 
m.p. 235-240°C (lit.(114) m.p. 239-243°C); ESI-MS (MH+= 168; MS/MS= 150, 137, 122, 93, 
82); and 1H NMR (DMSO-d6):  δ 4.32 ppm, 4.38 ppm (H-1); 6.78, 6.88 (H-3); 3.00, 2.8 (H-
4axial); 2.39 (H-4eq); 3.95, 4.07 (H-5); 1.79, 2.24 (H-6axial); 2.30, 2.26 (H-6eq); 2.34, 2.36 (H-
7axial); 2.0, 2.04 (H-7eq); 2.73, 2.65 (N-CH3).  
 
Anhydroecgonine Methyl Ester (AEME):  AE HCl (889 mg, 4.37 mmole) was dissolved in 13 
mL methanol and 0.05 mL of sulfuric acid and refluxed under N2 for 22 hours.  Upon cooling, 
the organic layer was evaporated in vacuo, dissolved in 20 mL distilled H2O and alkalinized to 
pH 9.6 with several drops of concentrated NH4OH.  The basic, aqueous layer was extracted 
several times with methylene chloride (35 mL), and then the organic layers were collected, 
dried over sodium sulfate, vacuum filtered, and evaporated in vacuo.  A crop of impure AEME 
free-base (209 mg, 1.15 mmole) was combined with fumaric acid (67 mg, 0.58 mmole) and 
dissolved in 1 mL boiling methanol.  The solution was allowed to boil for several minutes, 
cooled slightly in an ice bath and precipitated by the dropwise addition of ethyl ether (15 mL) 
to form a white precipitate, which was cooled overnight at 5°C.  After decantion of the ether 
layer, the precipitate was washed with cold acetone (30 mL), re-dissolved in boiling methanol, 
vacuum filtered through a 0.45 µm filter and evaporated to dryness.  AEME fumarate (133 mg, 
0.45 mmole) was analyzed by the following:  m.p. 175-177°C (lit.(115) m.p. 178-180°C); one 
single spot on TLC (Rf= 0.375 eluting on silica plates with glass backing, solvent system 
consisted of 2-propanol:10% NH4OH, 67:33); ESI-MS (MH+= 182, MS/MS= 168, 164, 151, 
150, 122, 118, 107, 105, 91, 82); 1H  NMR (DMSO-d6):  δ 3.87 ppm (H-1); 6.80 (H-3); 2.01, 
2.65 (H-4ax & eq); 3.41 (H-5); 1.56, 2.12 (H-6); 1.80, 2.12 (H-7); 2.37 (N-CH3); 3.68 (O-CH3); 
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6.56 (fumarate Hs); 13C NMR (DMSO-d6):  δ 58.2 ppm (C-1); 132 (C-2); 136.3 (C-3); 31.2 
(C-4); 56.9 (C-5); 28.7 (C-6); 33.2 (C-7); 35.5 (N-CH3); 51.6 (O-CH3); 166.8 (C=O).  Proton 
and carbon shift assignments were assisted by one-dimensional (1H, 13C) and two-dimensional 
(COSY, HETCOR) experiments, and previously reported 1H and 13C NMR spectra of AEME 
(62,111). 
 
2.2.2 Synthesis of 3-(N-Acetylcystein-S-yl)Anhydroecgonine Methyl Ester 
 AEME (250 mg, 1.38 mmole), prepared in the previous section (2.2.1), was combined 
with N-acetylcysteine (324 mg, 2.00 mmole) in 20 mL ammonium acetate buffer (0.01M,  
pH 7.8) and stirred under N2 in an ice bath for 24 hours.  After evaporation under reduced 
pressure, the solution was washed with cold acetone (10 mL) and further dried under vacuum.  
The residue was alkalinized and extracted several times with methylene chloride to remove 
free AEME.  AEME-NAC was purified by preparative HPLC, using a Econosphere C18, 10µ 
(250mm X 10mm) preparatory column (Alltech; Deerfield, IL), flow rate of 2.5 mL/min, UV 
detection at 220 nm, and a mobile phase consisting of acetonitrile:water (50:50) with the pH 
adjusted to 7.38 with a mixture of ammonium hydroxide/acetic acid.  Fractions collected from 
the LC peak eluting at 5 minutes were stored in 0.1% formic acid to increase stability.  Product 
was analyzed by several methods, including HPLC (tR = 5.0 minutes); ESI-MS (MH+= 345; 
MS/MS= 327, 313, 216, 182; MS3 of 216= 182); and 1H NMR (D2O): δ 4.15, 4.28 (H-1); 3.40, 
3.73 (H-2); 3.56, 3.60 (H-3); 2.59, 2.62 (H-4); 3.96, 4.03 (H-5); 2.20-2.60 (H-6); 2.20-2.60 (H-
7); 2.84, 2.86 (N-CH3); 3.80, 3.84 (O-CH3); 3.00 & 3.16, 3.04 & 3.21 (β-CH2); 4.35, 4.47 (α-
CH); 2.08 (acetyl methyl).   
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 A detailed NMR analysis of this compound included one-dimensional (1H, 13C, 
cycleNOE) and two-dimensional (COSY, HETCOR) experiments.  The 1H NMR of authentic 
N-acetylcysteine and cocaine HCl assisted in the proton assignments above, and are reported 
here:   
N-Acetylcysteine:  1H NMR (DMSO-d6):  δ 1.85 ppm (CH3); 2.40 (SH); 2.71, 2.81 (β-CH2); 
4.35 (α-CH); 8.15 (NH).   
Cocaine HCl:  1H NMR (DMSO-d6/ CDCl3):  δ 4.25 (H-1); 3.53 (H-2); 5.48 (H-3); 2.3, 2.40 
(H-4); 3.96 (H-5); 2.1, 2.3 (H-6); 2.13, 2.42 (H-7); 2.82 (N-CH3); 3.63 (O-CH3); 7.87 (C6H5-
Ha); 7.63 (C6H5-Hb); 7.49 (C6H5-Hc).  13C NMR (DMSO-d6/ CDCl3);  δ 62.8 ppm (C-1); 47.8 
(C-2); 63.7 (C-3); 32.3 (C-4); 62.4 (C-5); 22.2 (C-6); 23.8 (C-7); 38.8 (N-CH3); 52.2 (O-CH3); 
129 (C6H5-Ca); 128.3 (C6H5-Cb); 133.2 (C6H5-Cc).  Carbon shift assignments were also assisted 
by a one-dimensional DEPT experiment (spectrum not shown) and previous NMR data on 
cocaine and isomers reported by Carroll and co-workers (116). 
 
2.2.3 Synthesis of 3-(Glutathion-S-yl)Anhydroecgonine Methyl Ester 
 AEME free-base (10 mg, 0.055 mmole) was mixed with GSH (24 mg, 0.078 mmole) in 
2 mL of ammonium acetate buffer (0.063 M, pH= 7.8) and stirred under N2 for 19 hours.  The 
mixture was evaporated to dryness, the residue was dissolved in methanol (1 mg/mL) and a 5 
µL aliquot was injected onto a HPLC system (Waters) with the following conditions:  flow 
rate= 1.0 mL/min; UV detection at 220 nm; column= Zorbax SB-C8, 5µ (4.6mm X 250 mm) 
analytical column (Agilent; Palo Alto, CA).  A chromatographic peak at 2.50 minutes was 
collected and directly injected onto the ESI-MS:  MH+=489; MS/MS= 360, 182; MS3 of 360 = 
182. 
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2.2.4 Synthesis of 3-(Glutathion-S-yl)Anhydroecgonine 
  AE HCl (0.50 µmole in methanol) was combined with reduced glutathione (0.25 
µmole) and ammonium acetate buffer (0.1 M, pH= 7.4) to a final volume of 1.0 mL.  This 
mixture was stirred under N2 for 4 hours at room temperature and dried under vacuum to a 
gummy residue.  An aliquot (10 µg/mL in methanol) of the residue was injected directly onto 
an ion trap ESI-MS:  MH+= 475; MS/MS= 346, 290, 168; MS3 of 168= 150, 137, 122, 119, 93, 
91, 82. 
 
2.2.5 Synthesis of Anhydroecgonine Ethyl Ester (AEEE, EEG, ethylecgonidine) 
  Anhydroecgonine (AE) was synthesized from cocaine HCl as previously described.  
AE HCl (139 mg, 0.68 mmole) was dissolved in 10 mL absolute ethanol, 5 mL benzene and 
0.75 mL H2SO4.  The mixture was refluxed for three hours and cooled, following which 10 mL 
of absolute ethanol were added, and the mixture was refluxed for an additional 2 hours.  Upon 
cooling, the organic layer was evaporated in vacuo, the residue was dissolved in 8 mL distilled 
H2O and alkalinized with several drops of concentrated NH4OH to about pH 10.  The basic, 
aqueous layer was extracted several times with methylene chloride (30 mL), and then the 
combined organic layers were dried over sodium sulfate, vacuum filtered and evaporated in 
vacuo overnight.  AEEE free-base (54 mg, 0.28 mmole) was combined with fumaric acid (0.28 
mmole) and dissolved in 1 mL of hot ethanol.  The solution was cooled to room temperature, 
precipitated slowly by the dropwise addition of ethyl ether (5 mL), cooled overnight at 0°C, 
vacuum filtered and evaporated in vacuo to give AEEE fumarate (81.2 mg, 0.26 mmole):  m.p 
138-141°C (lit.(115) m.p. 144-146°C); GC-MS (195, 166, 138, 122, 94, 82); ESI-MS (MH+= 
196; MS/MS= 168, 150, 122, 108, 91; MS3 of 150= 132, 122, 109, 96, 93, 82); 1H NMR 
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(DMSO-d6): δ 3.84 ppm (H-1); 6.78 (H-3); 2.0, 2.65 (H-4); 3.39 (H-5); 1.54, 2.10 (H-6); 1.78, 
2.10 (H-7); 4.13 (O-CH2CH3); 1.22 (O-CH2CH3); 2.36 (N-CH3).   
 Proton chemical shift assignments were greatly assisted by the previously reported 
detailed NMR analysis of the related congener, AEME.  A small sample of AEEE fumarate (20 
mg) was shipped to the OCME of WV to serve as a reference standard in the identification of 
this potential transesterification product in the urine of known crack cocaine/ethanol users. 
 
2.3 Synthesis of the EA-SG Conjugate 
 The synthesis of the ethacrynic acid-SG (EA-SG) adduct was altered from a literature 
synthesis (80).  EA (100 mg, 0.33 mmole) and GSH (100 mg, 0.33 mmole) were dissolved in 
15 mL of a 50:50 mixture of absolute ethanol:water (solution was initially sparged by bubbling 
N2 through the solution for 15 minutes).  Next, approximately 12 drops from a saturated 
solution of sodium bicarbonate (pH 8.1) were added to the solution and the reaction was stirred 
under N2 at room temperature for 72 hours.  Upon reacting, the solution was evaporated in 
vacuo to a yellowish colored residue, dissolved in 2 mL of saturated NaHCO3 solution, and 
precipitated by the drop wise addition of 1% H3PO4 until persistent cloudiness.  Precipitate 
growth was maximized by storing at 0°C overnight.  Next, the aqueous layer was decanted, and 
then the filtrate was washed with cold methylene chloride (45 mL).  The filtrate was dissolved 
in warm methanol, vacuum filtered through a 0.45 µm filter, and evaporated in vacuo to obtain 
to obtain EA-SG (371 mg, 0.61 mmole).  EA-SG was analyzed by LC followed by direct 
injection ESI-MS analysis as follows:  HPLC conditions:  UV=220 nm; flow rate= 1.0 
mL/min; analytical column= Zorbax ODS, 5µ, 4.6 X 150mm; mobile phase contained 
methanol:water (40:60).  A small aliquot (0.5 mg/mL in methanol:water, 50:50) was injected 
 48
(10.0 µL) onto the HPLC and a chromatographic peak at 2.5 minutes was collected and 
directly injected onto the ion trap:  yield= 54%; m.p. 123°-125°C ; ESI-MS:  MH+= 610; 
MS/MS=535, 481, 463, 335; NMR (CD3OD):  δ 7.09 ppm (H-4); 7.58 (H-5); 3.21 (H-9); 1.32 
(H-10); 1.61, 1.79 (H-11); 0.910 (H-12); 5.00 (H-14); 4.58 (Cysα C-H); 2.79, 3.00 (Cysβ CH2); 
3.93 (Glyα CH2); 2.60 (Gluγ CH2); 2.18, 2.25 (Gluβ CH2); 4.08 (Gluα CH).   
 The 1H NMR (D2O) of commercially available reduced glutathione, which assisted in 
the proton assignments of EA-SG, is reported here:   
GSH:  δ 2.20 (Glu β-CH2); 2.59 (Glu γ-CH2); 2.97 (Cys β-CH2); 3.86 (Glu α-CH); 4.0 (Gly α-
CH2); 4.59 (Cys α-CH).        
 
2.4 Reaction of GSH with Michael Acceptor Compounds 
 Glutathione depletion over time was monitored by Ellmans method (117).  Ethacrynic 
acid (10 mM), arecoline (10 mM), AEME (10 mM) or acetaminophen (10 mM) were 
combined with reduced GSH (10 mM) and stirred under N2 at room temperature for 4 hours.  
Prior to reaction, the GSH solution was sparged under a strong stream of N2 to retard oxidation 
to the disulfide, GSSG.  In order to quantify the relative amount of GSH in solution over time, 
a small aliquot (20 µL) of solution was transferred into a 1.5 mL UV cuvette, then an excess of 
Ellmans Reagent (40 µL) and phosphate buffer (940 µL; pH 7.4; 100 mM) were added, and 
the absorbance at 412 nm was measured for three consecutive readings.  Mean absorbance 
measurements at each time point were converted to GSH concentrations by calculation from a 
seven point standard curve (r2= 1.0), computed from a regression analysis (Sigma Plot 2001, 
version 7.0) on a range of GSH concentrations from 0.008 mM to 0.5 mM.  Second order 
decay curves plotted for GSH concentrations versus time (2 to 240 minutes) for each 
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compound (Enzyme Kinetics, Sigma Plot) were acquired.  In addition, the relative 2nd order 
rate constants (k1) were derived from the slope of the line plotting GSH-1 versus time for 
ethacrynic acid, arecoline, AEME and acetaminophen.  The approximate half-life was 
calculated using the following equation: 
t1/2 = [k·C0]-1, where k= slope and C0= [GSH]initial 
 
2.5 Chemical Formation of the DCNB-SG Conjugate 
 The formation of the 3,4-dichloronitrobenzene-SG adduct (DCNB + GSH → DCNB-
SG) was monitored separately in the presence of AEME (10 mM), arecoline (10 mM) or EA 
(10 mM).  AEME free-base, arecoline free-base and EA were dissolved in DMSO; DCNB was 
dissolved in a mixture of methanol:water (70:30); and GSH was dissolved in THAM® buffer 
(0.1 M, pH 7.4).  Control solutions contained an equal amount of DMSO (181 µL) alone.  In a 
UV cuvette, DCNB (7 mM), GSH (3 mM) and reactive compounds (or DMSO alone) were 
briefly mixed by inversion, and the absorbance was measured at 345 nm every minute for 20 
minutes.  A background UV recording was performed on all compounds mixed briefly in the 
cuvette and used as the zero time point reading.  Mean absorbance recordings over 20 minutes 
(n=3) were plotted versus time and the corresponding line plots were generated by SigmaPlot 
2001.  Statistical analyses comparing the mean absorbance recordings versus control at 20 
minutes alone were performed with a one-tailed, students t-test.   
 
2.6 Degradation of Selected Glutathione Conjugates in Solution 
 Chemically synthesized arecoline-SG and AEME-SG were monitored for the retro-
Michael release of GSH into solution by a modification of Ellmans method (117).  Solutions 
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of AEME-SG (1 mg/mL), arecoline-SG (1 mg/mL) or glutathione (1 mg/mL) were prepared in 
THAM® buffer (0.1 M, pH= 7.4) to a total volume of 5 mL.  Reactions were stirred at 25°C 
under a gentle stream of N2.  Small aliquots (20 µL) were carefully withdrawn from solution at 
designated time intervals and reacted with Ellmans reagent, as described above (section 2.4), 
to obtain absorbance readings at 412 nm.  Complete time trials (2 to 240 minutes), performed 
on each compound, were repeated three times and the mean absorbance for each time interval 
was calculated.   
 To confirm the presence of conjugates in solution, small aliquots (20 µg/mL) of 
solution at approximately 5 minutes and 24 hours were directly injected onto the ESI-MS and 
monitored for the presence of adduct ions and original reactant ions.  Line plots depicting GSH 
concentrations versus time were generated for arecoline-SG and AEME-SG.  Kinetic constants 
describing the relative rate of degradation, calculated from the data, were consistent with a 
first-order rate of degradation.  
 
2.7 EA plus GSH in Human Liver Cytosol 
 A method to measure GSH conjugate formation and substrate depletion by cytosolic 
GSTs contained within human liver cytosol was derived from the following experimentation 
with the known GST substrate, EA.  First, a standard curve for detecting EA on HPLC was 
generated.  HPLC conditions:  UV detection (λ= 220 nm); Zorbax SB-C8 analytical column 
(4.6x150mm, 5µ); flow= 0.5 mL/min; mobile phase consisting of methanol:water (40:60); k' = 
5.0 minutes.  A six point linear standard curve was generated (r2= 1.0) for EA from 0.69 
mg/mL to 0.02 mg/mL injected onto column (5 µL).  EA (1 mM or 0.5 mm in methylene 
chloride) was combined with GSH (2 mM in buffer), pooled human liver cytosol (1 mg) and 
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ammonium acetate buffer (total solution volume= 1 mL).  Control solutions omitted EA, GSH 
or cytosol.  Total amount of methylene chloride was maintained at < 2% total organic volume.  
Vials containing cytosol were pre-incubated for 5 minutes at 37°C and the reaction was 
initiated by the addition of EA.  Total incubation time was 4 minutes, following which the 
enzyme was quenched by the addition of ice cold methanol (100 µL).  Next, vials were 
centrifuged at 10,000 rpm for 5 minutes (Eppendorf Mini Spin; Westbury, NY), and a small 
aliquot (5 µL) was injected onto the HPLC.  The area under the curve (AUC) for the EA UV 
peak was calculated (Millenium32, version 3.05.01) for each vial and quantified by regression 
analysis. 
 
2.8 Standard Curve of AEME on HPLC 
 AEME was evaluated on HPLC with the following conditions:  Zorbax SB-Phenyl 
reversed phase column (4.6 X 150mm, 5 µm); mobile phase consisting of 
acetonitrile:phosphate buffer (10 mM, pH 7.5) run at an isocratic ratio of 70:30; flow rate = 0.5 
mL/min; λ= 220 nm.  AEME concentrations ranging from 0.62 mg/mL to 0.019 mg/mL were 
injected (5 µL) onto column, and the area under the UV peak eluting at 10.7 minutes was 
computed by Millenium software.  The mean AUC (n=3) was plotted versus AEME 
concentration to generate a six point best-fit regression line by Sigma Plot (r2= 0.998).  The 






2.9 AEME plus GSH with Human Liver Cytosol 
 AEME (0.1 mM in 100% methanol), GSH (5 mM) and human liver cytosol (1 mg) 
were combined with phosphate buffer (pH 7.4) to a final volume of 1 mL.  Control solutions 
omitted AEME, GSH or cytosol.  Total [methanol] was 1.6% for each vial.  All samples were 
pre-incubated at 37°C for 4 minutes.  AEME was added in the final step and then the solutions 
were incubated at 37°C for one hour.  Following which, solutions were quenched by the 
addition of ice cold acetonitile/1% formic acid and centrifuged at 10,000 rpm for 5 minutes to 
separate the cytosol from solution.  Small aliquots of the supernatant in each reaction vial were 
injected separately onto the HPLC (conditions described in section 2.7) and analyzed for the 
presence of AEME that elutes at 11 minutes.  Mean AEMEAUC for each vial were tested for 
significance using a one-tailed Students t-test. 
 A second set of incubations were conducted to evaluate the effect, if any, of varying pH 
levels on AEME-SG formation in the presence of soluble GSTs.  AEME (0.5 mM, 0.25 mM 
or 0.125 mM in DMSO), reduced GSH (1 mM) and human liver cytosol (1 mg) were combined 
with phosphate buffer (0.1 M; pH 6.5, 7.4 or 8.5) and incubated at 37°C for 60 minutes.  
Control solutions contained either boiled cytosol or omitted AEME or GSH.  Total [DMSO] 
was 2.5% for each vial.   
 Following the incubation, vials were quenched with the addition (50 µL) of ice cold 
acetonitrile/0.1% formic acid, spiked with internal standard (cocaine HCl, 0.5 µg), and 
centrifuged for 8 minutes at 10,000 rpm.  A small aliquot (10 µL) was injected onto an LC-MS 
system containing a SB-phenyl (Zorbax) analytical column and a solvent system of 
acetonitrile:ammonium acetate (10 mM, pH 6.8) in a ratio of 70:30 flowing at 0.5 mL/min.  
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Monitoring in the positive ion mode, the presence of AEME-SG (MH+ 489), AEME (MH+ 
182), AE (MH+ 168), GSH (MH+ 308) and cocaine (MH+ 304) were detected for each vial.   
         
2.10 GST Activity after Exposure to AEME, Arecoline or EA 
 AEME (10 mM), arecoline (10 mM) or EA (5 mM) were separately combined with 50 
µL (1 mg) of pooled human liver cytosol and incubated at 37°C for 20 hours.  The GST 
activity of a 2 µL HLC sample was measured initially before drug exposure and after a 20 hour 
incubation at 37°C by a modification of the method described by Habig and co-workers (118).  
Briefly, DCNB (15 mM, 80 µL) and THAM buffer (100 mM, pH 7.42, 10 mL) were combined 
and pre-warmed at 37°C for five minutes.  Reaction mixture (990 µL) was combined with 10 
µL GSH solution (5 mM in distilled H2O) and 2 µL HLC in a UV cuvette, covered with 
parafilm, then mixed by inversion for 20 seconds.  A UV reading at 345 nm (published UV 
maximum of the DCNB-SG conjugate) was recorded every 15 seconds for one minute and a 
rate was calculated by the UV software (Beckman DU 640 spectrophotometer).  Absorbance 
readings acquired at 20 hours were subtracted from both the initial readings (t= 0) and non-
enzymatic chemical rate (blank).  Mean absorbance (n=4) measurements were converted to 
relative activity (velocity), and compared to control enzyme solutions void of any drug using a 
one-tailed Students t-test and F-distribution analysis (ANOVA).  Blank solutions contained no 
cytosol, while control solutions contained cytosol with equivalent amounts of solvent (3.0 µL 





2.11 Enzymatic Conversion of CDNB to CDNB-SG 
 Enzymatic activities of cytosolic GSTs towards CDNB, forming S-(2-chloro-4-
nitrophenyl)-glutathione (CDNB-SG) adduct in the presence of reduced GSH, was assayed 
spectrophotometrically according to Habig et al. (118).  Briefly, a reaction mixture containing 
THAM® buffer (0.1 M, pH 7.4) and CDNB (5 µM to 2560 µM in 100% methanol) were 
warmed to 37°C.  Reaction mixture (972 µL), 50% methanol (18 µL), GSH (1 mM in 
THAM®) and single donor human liver cytosol (4 µL; 0.08 mg protein/mL) were added to a 
UV cuvette, mixed briefly by inversion, and then placed into the spectrophotometer to measure 
the absorbance at 340 nm continuously for 20 seconds.  Following the short incubation, a 
relative rate (dA/min) was computed by the UV spectrophotometer software, and an apparent 
velocity (nmole product/mg/min) was calculated according to the following equation: 
 
  mean rate / [(volume of sample) × (protein concentration) × (0.0096 A/nmole)] 
 
 A blank UV recording performed prior to each analysis included all reaction 
components except GSH.  Trials for 20 seconds were repeated for at least six separate 
experiments for each CDNB concentration point.  Total methanol concentration was 
maintained at less than 5.0%, and was the same concentration for all incubation vials.  The 
non-enzymatic conjugation rate was also evaluated in a similar fashion, excluding cytosol.  
Average non-enzymatic rates were subtracted from the apparent mean enzymatic rates to 
obtain a truer rate estimate, which was used to calculate velocity (above equation) and further 
evaluated in a non Michaelis-Menten model and Eadie-Hofstee plot (Sigma Plot 8.0).  The 
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[CDNB] utilized in these plots was adjusted for a slight dilution, and corrected values varied 
by less than 10% from initial calculations (4.84 µM to 2358 µM).   
 
2.12 Inhibition of Cytosolic GST Activity by AEME 
 The enzymatic inhibition of CDNB-SG adduct formation in single donor human liver 
cytosol by the presence of AEME (0, 50, 125, and 320 µM) was evaluated.  Incubation 
conditions were adjusted from the above method (section 2.11).  In brief, incubations included 
reaction mixture (972 µL) containing CDNB (5 µM to 80 µM), AEME (0 µM to 320 µM in 50 
% methanol), GSH (1 mM) and cytosol (0.08 mg/mL).  Components were combined as 
described above to obtain an apparent rate over 20 seconds (n ≥ 6).  The non-enzymatic rate 
(excluding cytosol) was subtracted from the enzymatic rate to obtain an apparent velocity 
calculation.  Mean velocity calculations for AEME and CDNB concentrations were analyzed 
on a Lineweaver-Burk plot and Dixon plot, fitting the data to a non-linear regression model 
(Enzyme Kinetics Module, version 1.1.1).  
  
2.13.1 Solid Phase Extraction of Cocaine and Metabolites from Urine 
The solid phase extraction (SPE) method for analyzing cocaine and metabolites in urine 
was modified from a literature procedure (36).  One mL of blank urine was spiked with known, 
varied concentrations of AEME, AEEE, AEME-NAC or cocaine.  Urine from multiple drug 
overdose victims (obtained from the OCME of WV) was extracted under similar experimental 
conditions.  Varian Bond Elut Certify (130 mg/3 mL) cartridges containing a mixed mode 
sorbent with non-polar and cation exchange mechanisms were used.  Each SPE utilized an 
individual cartridge.  Extraction cartridges were subjected to reduced pressure (to facilitate 
 56
solvent flow) on a PrepTorr (Fisher Scientific) vacuum manifold connected to a water 
aspirator.   
Extraction was initiated by preconditioning the cartridge with 2 mL of acetonitrile (or 
methanol) at a flow rate under vacuum (8 kPa) of 0.75 mL/minute, followed by 3 mL of 
potassium phosphate buffer (0.1M, pH= 6.0).  Next, a well mixed, pre-prepared solution (5 
mL) consisting of 1 mL thawed urine diluted in 4 mL phosphate buffer, was loaded onto the 
extraction cartridge.  The cartridge was rinsed with 2 mL acetic acid solution (0.1M) followed 
by 3 mL of acetonitrile (or methanol), and the sorbent was dried under vacuum for one minute.  
The basic analytes were eluted with 6 mL of elution solvent consisting of a freshly prepared 
mixture of methylene chloride:2-propanol:22% ammonium hydroxide (78:20:2).  Elution 
solvent washed through the column was initially collected in 1.5 mL centrifuge tubes, then 
transferred to a small round bottom flask (10 mL), evaporated in vacuo at room temperature 
using a rotavapor apparatus, and further dried in a vacuum dessicator.  The small residue was 
carefully reconstituted in appropriate solvent and subjected to analysis via GC-MS, LC-MS, 
LC-MS/MS or direct inject ESI-MS. 
The limit of detection of AEME-NAC on LC-MS or LC-MS/MS was obtained by 
injecting a diluted series of known concentrations of confirmed AEME-NAC until detection 
was not observed, and then repeated for verification. 
 
2.13.2 Standard Curve of AEEE on GC-MS and LC-MS 
A five point linear standard curve (r2= 0.996) was generated on GC-MS by injecting 
authentic AEEE (in ethanol) in a concentration range of 0.4 to 6.3 µg/mL (tR = 4.7 minutes).  
On the LC-MS (Waters, Micromass) system a six point linear standard curve (r2= 0.999) was 
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created for AEEE in a range of 0.6 ng to 19 ng injected onto column (tR = 6.8 minutes).  For 
GC-MS, the abundance of ions 195 and 166 were monitored and quantified by HP software, 
and a linear regression line was computed (Sigma Plot 2001).  For LC-MS, the ion peak 
corresponding to MH+ 196 was integrated by MassLynx 3.5 software (Waters) and the 
resulting peak areas were quantified linearly by regression analysis (Sigma Plot 2001).   
 
2.13.3 Analysis of Urine from a Known Free-base Cocaine/Ethanol Abuser 
The case history for a drug overdose victim was obtained from James C. Kraner, Ph.D., 
Toxicologist at the Office of the Chief Medical Examiner in Charleston, WV. 
Case History:  The decedent, a 41 year old white male weighing 178 lbs. and standing 60 
tall, was found dead, collapsed outside his vehicle one morning.  His wife stated that he had 
left home after an argument at approximately 2330 hours.  A friend reported that the decedent 
had been out drinking the previous night.  The decedents wife stated that he had a history of 
alcohol and illicit drug use but that he had been clean for the past 6-7 weeks.   
Preliminary toxicological evaluation of the victim performed at the OCME is as 
follows.  The body was brought to the state medical examiners office and a complete autopsy 
was performed.  Blood alcohol concentrations were determined by direct injection GC-FID 
analysis using t-butanol as an internal standard.  Urine was screened for drugs of abuse and 
tricyclic antidepressants by enzyme mediated immunoassay (EMIT) using a Roche Cobas Mira 
with kits purchased from Dade Behring (Cupertino, CA).  Urine was also screened for basic 
drugs using the Toxi-Lab A extraction system (Varian Inc.; Walnut Creek, CA) with Proadifen 
(SKF-525A) added as an internal standard.  After a 20 minute period in which the sample was 
inverted then centrifuged, the organic layer was evaporated to dryness and reconstituted with 
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75 µL of ethyl acetate.  One microliter was injected onto an Agilent 6980/5973 GC-MS and 
analyzed in full scan mode.  Peak identification was accomplished by comparison to a house 
mass spectral library, the AAFS drug library and the National Institute of Standards and 
Technology (NIST) 2002 library.  Confirmation and quantitation was by GC-MS.  Oxycodone 
was present in the subclavian blood at 4.40 mg/L and methadone at 0.25 mg/L.  Cocaine was 
confirmed at < 0.05 mg/L, benzoylecgonine at 0.18 mg/L and ethanol at 0.10%.  Other 
compounds identified in the urine but not quantified include AEME, AEEE, cotinine, and two 
methadone metabolites, EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) and 
EMDP (2-ethyl-5-methyl-3,3-diphenylpyrroline).  Cause of death was combined oxycodone, 
methadone, cocaine and alcohol intoxication.  The manner of death was accidental. 
In our laboratories, 1 mL of urine from this victim was subjected to SPE as described 
above, and peaks (or known fragments) corresponding to AEEE were compared to authentic, 
synthesized standard, quantified on GC-MS and LC-MS, and identified by LC-MS/MS. 
 
2.14.1 Lung A549 Cells Exposed to AEME, AEEE, and AE  
 A549 lung fibroblast cells were seeded in 24-well plates (3.75 × 105 cells/well) and 
incubated at 37°C with 5% CO2 for 48 hours until roughly 80% confluence was observed 
microscopically.  Cells were washed with 1 mL of Hanks balanced salt solution, then 1 mL of 
HyQ Hams/F-12 media was added to each well.  Confirmed AEME fumarate (1 mM, 0.5 mM 
and 0.25 mM in DMSO), AE HCl (1 mM in DMSO), and AEEE fumarate (1 mM in DMSO) 
were added to cells in triplicate.  Control wells (also created in triplicate) included 0.10% ethyl 
alcohol, 18 µL DMSO (2%), or nil.  Cells were incubated at 37°C with 5% CO2 for 24 hours.  
Following incubation, media was removed and the cells were trypsinized by the addition of 
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500 µL trypsin/0.25% EDTA.  Upon another short incubation, 10 µL of cell solution were 
combined with 99 µL trypan blue (0.4%) in a 96 well culture tissue plate.  Five µL of the 
resulting mixture were pipetted onto the hemacytometer and the percent cell viability was 
calculated, as observed under microscope for 5 separate grids, using the following equation: 
 
% cell viability = # viable cells per grid / # total cells per grid × 100% 
 
 Viable cells were counted as such if they displayed no staining, whereas dead cells 
exhibited uptake of the trypan blue dye, which readily permeates damaged or destroyed 
cellular membranes.  The calculated mean percent viability for each compound was compared 
to control cells only spiked with DMSO.  Significant variability in cell viability was tested by 
the students t-test, using a one-tailed test.   
 
2.14.2 A549 Cell Cytotoxicity Observed by Flow Cytometry 
 Lung A549 fibroblast cells were prepared as described above (section 2.12.1).  
Following incubation for 48 hours, confluent cells were separately spiked (in duplicate) with 
the following compounds:  20% ethyl alcohol, DMSO, DMSO + distilled water, NAC (5 mM 
in distilled water), styrene oxide (1 mM in DMSO), AEME fumarate (1 mM, 0.5 mM or 0.25 
mM in DMSO), AE HCl (1 mM in DMSO), AEEE fumarate (1 mM in DMSO), cocaine HCl 
(1 mM in DMSO), AEME (1 mM, 0.5 mM or 0.25 mM) plus NAC (5 mM), AE (1 mM) plus 
NAC, AEEE (1 mM) plus NAC, styrene oxide (1 mM) plus NAC.  The final concentration of 
DMSO in each cell was 2 % (v/v) or less.  Cells were then incubated for 24 hours at 37°C with 
5% CO2, following which, images where captured of each well for comparison.  Media was 
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removed and set aside, and then the cells were trypsinized by the addition of trypsin with 0.5% 
EDTA.  Saved media was centrifuged and the resulting pellet was combined with trypsinized 
cells to achieve a final cellular mixture.  Solutions were spiked with 2 µL propidium iodide, 
transferred to a 10 mL test tube, and analyzed on a flow cytometer located in the WVU Core 
Facility.  A region of increased fluorescence was indicative of cellular death and the percentage 
of dead cells was computed.  Comparisons between compounds and control (DMSO alone) 

























3.  Results 
 
3.1 Synthesis of Arecoline Congeners 
 The ESI-MS, MS/MS and MS3 spectra of the chemically synthesized arecoline-NAC 
adduct are presented below (Fig. 3.1).  The full scan spectrum of arecoline-NAC (Fig. 3.1.A) 
shows a low intensity ion peak (MH+ 156) corresponding to arecoline, suggesting that the final 
product was not pure.  However, the 1H NMR spectrum of arecoline-NAC (not shown) 
indicates pure product, as the vinylic proton (ca. 7.0 ppm) corresponding to arecoline alone 
was not observed.  Therefore, it is likely that the electrospray analysis of arecoline-NAC 
facilitated some retrogression of the adduct to starting materials. 
 Propyl ester salts (hydrochloride and sulfate) of arecaidine were also synthesized and 
exhibited a slightly greater retention time on TLC analysis, as compared to arecoline, the 
methyl ester, and standard, arecaidine (Rf=  0.8, 0.78 and 0.0, respectively).  The full ESI-MS 
scan of the chemically synthesized arecoline-SG conjugate showed the parent ion (MH+ 464), 
Na+ adduct (MH+ 486) and a fragment (MH+ 335), which represents the loss of a glutamic acid 
moiety (Fig. 3.2.1), a commonly seen fragment when analyzing glutathione adducts on ESI-
MS.  Interestingly, ESI-MS analysis (spectra not shown) of a small aliquot of the synthesized 
arecaidine propyl ester-SG adduct (10 µg/mL in methanol) showed two predominant ion peaks 
(MH+ 492 and 464), representing the propyl ester and methyl ester adducts, respectively.  
Apparently, the ESI process, in the presence of an excess of methanol, catalyzed the propyl to 




3.2 Synthesis of AEME, AEEE and Derivatives 
 Starting with cocaine HCl, AE HCl, then AEME fumarate was synthesized and the 
NMR spectra are reported for AE and AEME (Fig 3.3, 3.4.1 and 3.4.2).  AEME-NAC was 
synthesized from AEME, and the proton assignments, as well as stereochemical assignments 
about C-2 and C-3 were elucidated (Fig 3.2.2 and 3.5).  The ESI-MS spectra of AEME-NAC 
and AEME-SG are reported below (Fig 3.6 and 3.7, respectively), providing additional 
structural evidence of each compound.  The specific mass fragmentation patterns of AEME-
NAC are included in Fig 3.2.1.   
 1H and COSY spectra (Fig 3.5) of AEME-NAC present fairly equally intensive peaks 
for most of the protons (53:47).  The stereochemistry of AEME-NAC was evaluated using the 
one-dimensional cycleNOE experiment.  Parameters for this experiment were optimized on 
two individual reference solutions, dimethyl acrylic acid (10 mg in DMSO-d6) and camphor 
(15 mg in DMSO-d6).  Saturation of the H-2 peak on AEME-NAC (3.4 ppm) resulted in NOE 
effects of H-1 (4.28 ppm), H-3 (3.6 ppm) and H-4 (2.6 ppm).  Saturation of the other peak 
corresponding to H-2 (3.37 ppm) resulted in only one NOE effect of H-1 (4.17 ppm).  These 
findings are consistent with the epimers drawn below (Fig 3.2.2). 
 AE-SG was also synthesized and the adduct ion of MH+ 475 (MS/MS: 346, 308, 168) 
was detected by ESI-MS (spectrum not shown).  The relative amount of AE-SG formed was 
less than the amount of glutathione adducts formed by using similar synthetic procedures with 
arecoline, AEME and ethacrynic acid.  The ethyl transesterification product of AEME in the 
presence of ethanol, AEEE, was also synthesized.  A 1H NMR spectrum of AEEE fumarate is 
included below (Fig 3.8). 
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3.3 Synthesis of the EA-SG Conjugate 
 EA-SG phosphate, a potent inhibitor of cytosolic GSTs, was chemically synthesized.  
An ESI-MS scan of the LC-collected product detected an adduct ion, MH+ 610, and adduct ion 
fragments on MS/MS:  MH+ 481 and 335 (spectra not shown).  NMR spectra of the adduct is 
shown below (Fig 3.9).  Our NMR spectra shows evidence of two diastereoisomers, and our 
proton assignments are consistent with those reported in the literature (109).  
   
3.4 GSH Depletion by Michael Acceptor Compounds 
 The relative rate of glutathione depletion over time in the presence of reactive 
compounds was assessed by Ellmans method (117).  Glutathione concentration versus time 
was charted for each compound (arecoline, ethacrynic acid, acetaminophen and AEME) and 
included below (Fig 3.10, 3.11).  The control reaction included acetaminophen (10 mM), 
which has no appreciable reactivity with GSH.  Calculated GSH concentration values were the 
arithmetic mean of three separate experiments.  Some additional graphs were created depicting 
GSH-1 concentration versus time and log [GSH] versus time.  The log [GSH] versus time 
graphs (not shown) were not linear, suggesting that the reaction is not of the first order.  Slopes 
(mM-1min-1), or second order rate constants (k1), of the best-fit linear regression lines for each 
compound (Fig 3.12.1, 3.12.2) and calculated half-life values (min) are as follows:  arecoline 
(2.2 × 10-1, 14.7), ethacrynic acid (4.1 × 10-1, 5.3), AEME (6.8 ×10-3, 459), and acetaminophen 





3.5 Chemical Formation of the DCNB-SG Adduct 
 The chemical formation of the DCNB-SG conjugate was monitored in the presence of 
EA (10 mM), arecoline (10 mM) or AEME (10 mM).  Collected data points were plotted over 
time and included below for each compound beside control (Fig. 3.13, 3.14, and 3.15).  EA  
(p < 0.005), arecoline (p < 0.025) and AEME (p < 0.100) exhibited a significantly reduced 
absorbance reading at 20 minutes compared to control.  The AEME trial contained greater 
variance; therefore, it was found only significant at the 10% level, in spite of the pronounced 
reduction in conjugate formation over 20 minutes, as compared to arecoline.   
 
3.6 Degradation of Selected Glutathione Conjugates in Solution 
 Synthetically prepared arecoline-SG and AEME-SG conjugates were dissolved in 
buffer at physiological pH and the approximate rate of glutathione release over time was 
measured using Ellmans reagent.  The measured extent of glutathione appearance over time is 
charted below for both conjugates (Fig 3.16).  The negative control, GSH alone (1 mg/mL) in 
buffer, exhibited no significant changes in concentration over time (data not shown).  
Assuming a first-order rate of degradation, the relative rate constants (k-1) for arecoline-SG and 
AEME-SG decay were calculated from the slope of the regression line fitting log [GSH] versus 
time (2.1 × 10-5 and 3.9 × 10-4, respectively).  Although the calculated rate of degradation for 
AEME-SG was approximately 19-fold greater than arecoline-SG, the AEME-SG rate indicates 
only minimal reversion to the original reactants over 24 hours.  The measured amount of GSH 
in AEME-SG solution after 4 hours was merely 0.005 mM, representing less than 1% 
degradation. 
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 Direct injection ESI-MS was applied to detect adduct ions in the tested buffered 
solutions initially and 24 hours later.  Chemical structures for arecoline-SG (MH+ 463) and 
AEME-SG (MH+ 489) were confirmed by MS/MS and MS3 for each ion at 0 and 24 hours 
later, providing additional evidence of the stability for both conjugates at the tested pH and 
temperature.   
 
3.7 EA + GSH in Human Liver Cytosol 
 HPLC with UV detection of EA (k'= 5.5 min) quantified the amount of EA in each 
reaction vial following a 4 minute incubation at 37°C.  In one incubation set, reaction vials 
containing EA (0.5 mM), GSH (2 mM) and cytosol (1 mg) contained less EA than vials with 
EA and GSH only (0.28 µg and 0.97 µg, respectively).  A summary of incubation conditions 
and results is contained within Tables 3.1.1 and 3.1.2, and a portion of representative 
chromatograms for the analysis of two different reaction vials from the same incubation is also 
included below (Fig. 3.17).    
 
3.8 AEME + GSH in Human Liver Cytosol 
 The first set of incubations utilized HPLC with UV detection to identify and quantify 
AEME in each reaction vial following a 60 minute incubation at 37°C.  Preparations 
containing AEME, GSH and HLC contained significantly less AEME (Fig. 3.18) than 
preparations lacking HLC (p < 0.005). 
 In the second array of incubations, LC-MS was employed for detection of AEME-SG 
formation at varying pH levels.  At all tested AEME concentrations (0.5 mM, 0.25 mM and 
0.125 mM) we found no appreciable difference between vials containing viable HLC versus 
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those with boiled cytosol.  Similarly, adjusting the incubation buffer pH from 6.5, 7.4 or 8.5 
did not significantly alter product formation between the two preparations. 
 
3.9 GST Activity after Exposure to AEME, Arecoline or EA 
 HLC (40 µg) was incubated at 37°C with AEME (10 mM), arecoline (10 mM) or EA (5 
mM) for 20 hours.  Following which, the GST activity (pmole product/mg/min) was measured 
as the rate of formation of the conjugate, DCNB-SG, as measured by the increase in 
absorbance at 345 nm (Fig. 3.19).  AEME and EA substantially reduced GST activity  
(p < 0.005) after 20 hours.  Arecoline, however, displayed considerable variability in the 
reduction of GST activity and was not found to be statistically significant from cytosol control.     
 
3.10 Enzymatic Conversion of CDNB to CDNB-SG 
 Single donor HLC (0.08 mg/mL) was briefly incubated over 20 seconds at 37°C in the 
presence of GSH (1 mM) and various concentrations of CDNB (5 µM to 2560 µM).  CDNB 
concentration points versus mean apparent velocity (nmole product/mg protein/min), 
calculated from the apparent rate derived from the non-enzymatic rate subtracted from the 
enzymatic rate, are depicted in a non-Michaelis-Menten plot (Fig 3.20).  An Eadie-Hofstee plot 
(Fig. 3.21) was also generated from the data, depicting velocity versus velocity/ [CDNB], and 
also suggests a biphasic or atypical kinetic profile for this reaction (119). 
 
3.11 Inhibition of Cytosolic GST Activity by AEME 
 In an analogous fashion to the aforementioned experiments (section 3.10), single donor 
HLC (0.08 mg/mL), GSH (1 mM), CDNB (5 µM to 80 µM) and AEME (0 µM to 320 µM) 
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were incubated at 37°C for 20 seconds.  The apparent velocity was calculated after 20 seconds 
(n=6) and an evaluation of the type of inhibition was performed using simulated enzyme 
kinetics software (Enzyme Kinetics Module, version 1.1.1).  The software fit the experimental 
data best to a competitive and mixed inhibition model (r2= 0.985 and 0.986, respectively).  A 
Lineweaver-Burk plot (Fig. 3.22.1), depicting 1/velcocity versus 1/ [CDNB] for four fixed 
AEME concentrations (0, 50, 125, and 320 µM), and Dixon plot (Fig. 3.22.2), depicting 
1/velocity versus AEME concentration, are displayed for a mixed (full)-linear inhibition 
model.  The following kinetic parameters, Vmax (nmole/mg/min), Km (µM), and Ki (µM) 
values, were derived from the analysis:  311, 96, and 334, respectively.  The relative inhibition 
constant, Ki, was calculated for the mixed (334 µM) and competitive (262 µM) models, 
indicating that AEME is a weak inhibitor of cytosolic GST activity.   
  
3.12 Solid Phase Extraction of AEME-NAC 
 Blank urine was spiked with varying concentrations of authentic AEME-NAC and 
extracted by solid phase extraction.  Using direct injection ESI-MS, the limit of detection of 
AEME-NAC was approximately 15 ng/mL.  A positive identification of the adduct ion in the 
blank urine sample included three data points, including full scan (MH+ 345), MS/MS (MH+ 
216 and 182), and MS3 of 216 (MH+ 182).  The limit of detection on LC-MS was 
approximately 1.9 ng, whereas the detection limit on LC-MS/MS was nearly 50 ng.  Using 
SPE followed by direct injection ESI-MS, LC-MS or LC-MS/MS analyses, we were unable to 
detect this adduct in the urine of two different known crack cocaine users, obtained from the 
OCME of West Virginia.    
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3.13 Analysis of the Urine from a Known Free-base Cocaine/Ethanol Abuser 
 Three different analytical approaches were employed to analyze the urine of a decedent 
who co-abused freebase cocaine and ethanol.  AEEE was identified in a urine sample that also 
contained cocaine, cocaethylene and AEME.  By GC-MS, the peak eluting at 4.67 minutes 
corresponded to AEEE (Fig 3.23).  By comparison with a standard curve, the approximate 
concentration of AEEE in the urine sample was about 1.0 µg/mL.  The other compounds, 
although not quantified, exhibited the following retention times (min):  AEME (4.28), cocaine 
(8.79), cocaethylene (9.04).  A comparison of peak heights from 0 to 12.5 minutes showed 
relative concentrations of AEME, cocaine and cocaethylene.  The relative peak height ratio of 
AEME:AEEE was 1.5:1.  In addition, the relative peak height ratio of cocaine:cocaethylene 
was 1.7:1, whereas the ratios of cocaine or cocaethylene to there related breakdown product, 
AEME or AEEE, was 2.8:1 and 2.4:1, respectively.  The possibility that AEEE is an artifact 
produced in the GC injector port by thermal decomposition of cocaethylene was not ruled out.   
 To address the possible thermal breakdown of cocaethylene on GC-MS, an analytical 
process was applied for the detection of AEEE that would have less potential for producing 
AEEE as an artifact.  Urine from the same overdose victim was analyzed by SPE followed by 
LC-MS (Fig 3.24).  Reconstituted urine SPE extract (40 µL) was injected and the 
corresponding compounds (with retention times in minutes) were detected:  AEME (6.63), 
AEEE (6.83), cocaine (7.33) and cocaethylene (8.13).  Relative peak height ratios were as 
follows:  cocaine:cocaethylene (1.6:1); AEME:AEEE (3.5:1); cocaine:AEME (1381:1); and 
cocaethylene:AEEE (3812:1). 
 Authentic AEEE (10 µg/mL in acetonitrile) was injected directly into an ion trap ESI-
MS and the mass fragmentation was recorded.  Confirmed AEEE in a similar concentration 
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was injected (20 µL) onto the LC-MS (Shimadzu/ Thermoquest system) and MS/MS analysis 
on the parent mass, MH+= 196, with collision energy of 20%, was performed up to 15 minutes.  
In the urine sample, a low intensity ion peak at a similar retention time to standard, ca. 8.44 
minutes, was detected for the following MS/MS ions:  168, 150, 122, and 91, confirming the 
presence of AEEE in the sample.  An additional ion peak at 10.42 minutes was assigned as 
cocaethylene based on an analysis of its mass spectrum.  It is interesting to note the presence of 
a cocaethylene fragment at the same m/z value as the AEEE MH+ ion (m/z 196), indicating that 
the ESI ionization process produces the same product as does thermal degradation.  Thus, 
separation of AEEE from cocaethylene by LC or other chromatographic processes is necessary 
to give an accurate identification of AEEE. 
 Two different control urine samples were analyzed under the same experimental 
conditions as the case sample.  LC-MS (Waters/Micromass system) on a 1 mL blank urine 
sample showed no trace of cocaine, cocaethylene, or pyrolysis products.  Another urine sample 
obtained from the OCME was analyzed, and the compounds identified included cocaine and 
AEME.  This sample contained no detectable levels of either cocaethylene or AEEE. 
 
3.14 Lung A549 Cells Exposed to AEME, AEEE, and AE  
 The percent cell viability of A549 lung fibroblasts exposed to cocaine pyrolysis 
products for 24 hours was measured by a trypan blue exclusion dye assay.  Mean percent 
viability (n=3) for each compound and controls are depicted below (Fig. 3.25).  Viability of 
cells exposed to AEME (1 mM) or AEEE (1mM) were significantly less than 2% DMSO 
control (p < 0.01).  AEME (0.5 and 0.25 mM) and AE (1 mM) exposed cells also exhibited 
significantly less cell viability (p < 0.005).  Their greater level of significance resulted from 
 71
less variance among the 3 tested wells, even though AEME (0.5 and 0.25 mM) contained 
greater percent viabilities (Fig. 3.25) than AEME (1 mM) or AEEE (1mM). 
 
3.15 A549 Cell Cytotoxicity Observed by Flow Cytometry 
 Percentages of dead cells, resulting from a 24 hour incubation with various compounds 
were calculated by flow cytometry and averaged (Table 3.2).  DMSO control (2%) exhibited a 
high percentage of cellular death (45%), resulting in weak comparisons with other cells spiked 
with cocaine and pyrolysis products.  1 mM of AEME fumarate (46%) did exhibit a greater 
percentage of cell death than 1 mM of cocaine HCl (37%), but only significant at the 10% 
level.  AEEE fumarate (1 mM) showed the greatest percentage of cell death (57%) of the tested 
cocaine pyrolysis products.  Styrene oxide (1 mM) displayed similar toxicity as 20% ethanol 
(87% and 87.2%, respectively) to A549 cells, and clearly more toxic than cocaine or any of the 
pyrolysis products.  The addition of NAC (5 mM) to styrene oxide, AEME, AEEE and AE was 
also tested in duplicate in this cell line (Table 3.3).  Although the addition of NAC appears to 
lower cell toxicity with styrene oxide, AEME (1.0, 0.5, and 0.25 mM), AEEE (1 mM) but not 









Figure 3.1:  ESI-MS spectra of arecoline-NAC adduct.  (A) Full scan.  (B) MS/MS 
fragmentation of the protonated adduct ion at m/z 319.  (C) MS3 of the fragment ion, m/z 190, 
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Figure 3.2.1:  Mass fragmentation patterns of the synthesized arecoline-SG and AEME-NAC 































Figure 3.2.2:  Chemically synthesized AEME-NAC epimers.  A is the 2β,3α isomer, while B 




































Figure 3.6:  ESI-MS spectra of synthesized AEME-NAC.  (A) Full scan.  (B)  MS/MS of 
adduct ion, producing the primary fragments: MH+ 327, 216 and 182.  (C) MS3 of fragment ion 









Figure 3.7:  ESI-MS spectra of synthesized AEME-SG.  (A) Full scan.  (B) MS/MS of adduct 
ion MH+ 489, producing the ion fragments, MH+ 360 and 182.  (C) MS3 of fragment ion MH+ 










































































































Fig. 3.16:  The slow degradation of chemically synthesized AEME-SG (1 mg/mL) and 





Reaction Vial [EA] [GSH] HLC Total Volume 
#1 1.0 mM 2 mM 1 mg 1.0 mL 
#2 1.0 mM 2 mM ----- 1.0 ml 
#3 0.5 mM 2 mM 1 mg 1.0 mL 
#4 0.5 mM 2 mM ----- 1.0 mL 
 
 





Reaction Vial EA Peak Area [EA] 
#1 5.5 × 106 0.86 µg 
#2 1.5 × 107 2.32 µg 
#3 1.8 × 106 0.28 µg 
#4 6.3 × 106 0.97 µg 
 
 







Fig. 3.17:  Sample HPLC chromatograms following 4 min. incubation from the conditions 










Figure 3.18:  AEME depletion in preparations with or without human liver cytosol after 60 









Figure 3.19:  Reduction of presumed cytosolic GST activity by AEME (10 mM) and EA (5 
















Fig 3.20:  CDNB-SG conjugate formation by HLC (0.08 mg/mL) fitted to an atypical or non-









Fig 3.21:  Eadie-Hofstee plot of CDNB-SG conjugation by HLC, providing further evidence of 
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Fig 3.22.1:  Lineweaver-Burk plot showing mixed-linear inhibition of cytosolic CDNB-SG 
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Fig 3.22.2:  Dixon plot representing mixed-linear inhibition of cytosolic GST activity by 









Fig. 3.23:  GC-MS spectrum of the decedents urine following SPE, showing total ion current (top 
spectrum).  The fragmentation spectrum (bottom spectrum) of the peak at 4.7 minutes structurally 







Fig. 3.24:  LC-MS spectra (selected ion monitoring) of the decedents urine sample following 
SPE.  The appropriate protonated ion mass is indicated to the right of each SIM chromatogram, 
and the relative intensity (top left) for each compound were normalized from the most intense 








Fig. 3.25:  Calculated percent cell viability of A549 lung fibroblasts based on trypan blue 
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Table 3.2:  Tabulation of cellular death to A549 lung fibroblasts, as measured by flow 
cytometry, following exposure to various compounds, including styrene oxide and cocaine 
pyrolysis products. 
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Table 3.3:  Apparent effect of NAC addition on the toxicity of A549 cells induced by styrene 
























 Our studies presented here contain biological significance.  The following questions 
developed early during our investigations:  Does the in vivo metabolism of AEME to AEME-
SG occur in known free-base cocaine users?  If so, does this phenomenon have toxicological 
implications, or represent the formation of an additional metabolite for identification of crack 
cocaine use in a forensic laboratory?  Some of our initial studies have primarily addressed 
these questions.  Firstly, the relevance of AEME-SG conjugate formation in vivo from 
primarily in vitro data is discussed. 
 We have demonstrated the chemical synthesis of AEME conjugates, mainly AEME-
NAC and AEME-SG, and verified the chemical structures by NMR and multistage ESI-MS.  
Interestingly, the chemical synthesis of AEME-NAC resulted in two epimers (Fig. 3.2.2).  
Epimer A results from NAC addition on the endo side of AEME, due to increased steric 
hindrance produced by the N-methyl on the exo side of the ring.  The structure of epimer B is 
speculated from previous work on phenylthio derivatives of AEME (120).  It is likely the result 
of base-catalyzed epimerization of epimer A at C-2 in an attempt to reduce steric repulsion 
between the N-methyl and carbonyl groups (120).   
 In order to further study the Michael addition of GSH to electrophiles we utilized 
Ellmans method (117) to quantify GSH concentrations over time in the presence of AEME, 
ethacrynic acid or arecoline.  Diagnostic graphs depicting log [GSH] versus time (not shown) 
were not linear; therefore, we assumed a 2nd order reaction for all compounds (A + B  
C), first-order in each reactant.  Thus, we calculated relative 2nd order rate constants (k1) for 
AEME (6.8 × 10-3), arecoline (2.2 × 10-1) and ethacrynic acid (4.1 × 10-1).  Furthermore, 
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AEME reduced GSH concentrations by approximately 30%, whereas arecoline and ethacrynic 
acid reduced GSH by nearly 95% and 98%, respectively.   
 Largely, the observed AEME rate suggests that chemically, AEME reacts slowly with 
GSH.  We speculate that the observed slower reactivity of AEME with GSH, compared to the 
chemically similar arecoline, is due to the presence of an additional two carbon methylene 
bridge on AEME, producing increased steric hindrance that potentially slows nucleophile 
addition.  EA chemically contains a methylenebutyryl side chain with an α,β-unsaturated 
ketone moiety that is freer to react with nucleophiles than AEME or arecoline, which contain a 
more complicated ring structure.  Moreover, it is likely that the ketone moiety on EA is capable 
of producing greater stabilization of the carbanion, on C-9 or C-10, following nucleophile 
addition, increasing conjugate formation.  
 Habig  et al. (118) reported the extinction coefficient (mM-1cm-1)  and maximum 
absorbance wavelength (nm) of 3,4-dichloronitrobenzene (DCNB) and 1-chloro-2,4-
dinitrobenzene (CDNB):  8.5, 345; 9.6, 340, respectively.  Both aromatic compounds are 
substrates for cytosolic GSTs, readily react with free sulfhydryls, and commonly utilized in 
GSH experiments.  AEME significantly slows the chemical conversion of DCNB to DCNB-SG 
(Fig 3.15).  In contrast to the chemical reaction studied by Ellmans method (Fig 3.11.B), 
AEME reduced the chemical formation of DCNB-SG intermediary to EA and arecoline.  One 
source of error in these experiments involves the potential conversion of DCNB to a 
hydroxylated metabolite, which likely contains a strong absorbance at 345 nm.  Chiefly, these 
experiments are also suggestive of AEME reacting with GSH. 
    Despite moderate reactivity with GSH, the potential for AEME as a substrate for 
cytosolic glutathione S-transferases was postulated, and is certainly biologically significant.  If 
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found as a substrate for GSTs, then the likelihood of detecting AEME conjugates in biological 
fluids of free-base cocaine users increases.  In the presence of pooled HLC and reduced GSH, 
AEME concentration was significantly reduced in comparison to control vials lacking HLC.  
However, the high likelihood of liver esterases being present in the HLC may catalyze the 
hydrolysis of AEME to AE, a polar, amphoteric compound that elutes quicker than AEME on 
our HPLC system.  A second array of experiments using LC-MS found no statistical difference 
in AEME-SG formation between native cytosol versus boiled cytosol preparations.  
Furthermore, varying pH levels appears to not appreciably alter product formation.  Therefore, 
in our hands we report no clear evidence suggesting that AEME is a substrate for soluble 
GSTs contained within human liver cytosol.  One explanation for the lack of enzyme catalysis 
in our experiments includes the possibility that AEME inhibits or blocks GSTs.  We have 
shown that AEME and EA, a known GST inhibitor, significantly reduce GST activity towards 
DCNB-SG conjugation after a 20 hour incubation (Fig 3.15).   
 Since these preliminary GST inhibitory experiments were only suggestive, we then 
engaged in a more detailed kinetic analysis to study the potential of AEME as an inhibitor of 
cytosolic GSTs.  If discovered as a GST inhibitor, chronic AEME exposure may potentially 
predispose chronic free-base cocaine users to toxicity from electrophilic xenobiotics that are 
normally detoxified by GSTs.  Several studies have shown a predisposition to cancer 
development in cocaine smokers (121,122), and chemical carcinogens are often electrophilic 
agents that are also substrates for GSTs (77). 
 Using CDNB (1-chloro-2,3-dinitrobenzene) as a probe GST substrate, we observed an 
atypical or non-Michaelis-Menten kinetic profile (Fig. 3.20) in the presence of an excess of 
GSH (119).  Although an ordered sequential pathway with high GSH concentrations and a 
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ping-pong pathway at low concentrations of GSH have been postulated regarding the GST 
kinetic mechanism (123), most studies support the idea that the kinetic mechanism is random 
sequential (124-126).  The studies do agree that the kinetic profile is biphasic, which agrees 
with our current findings.  Our Eadie-Hofstee plot (Fig. 3.21) is also indicative of a biphasic 
kinetic mechanism (119).  The presence of multiple isoforms of GSTs in human liver cytosol 
may also complicate kinetic analysis. 
 After studying the inhibition of cytosolic GST activity by AEME, the type of inhibition 
was diagnosed as a mixed (full)-linear model (α > 1, β = 0), based on correlation coefficients.  
Mixed inhibition, containing a likely combination of competitive (increase in Km) and pure 
non-competitive inhibition (decrease in Vmax with no overall change in Km) (127,128), was 
previously observed with ethacrynic acid towards GSTs (80,129).  Ethacrynic acid (Ki  < 10 
µM) strongly competes competitively with CDNB while showing non-competitive inhibition 
towards GSH (80).  Based on our current data, a similar scenario is postulated to occur with 
AEME (Ki = 334 µM), CDNB and GSH.  To conclude, AEME is a weak inhibitor of cytosolic 
GSTs, suggesting limited biological significance since only a small proportion of free-base 
cocaine is thermolytically converted to AEME (≤ 5%), leading to low physiological serum 
levels, and AEME retains an overall insubstantial Ki constant compared to other known GST 
inhibitors.    
 The relative rate of degradation of chemically prepared arecoline-SG and AEME-SG is 
reported here.  Both conjugates exhibited insignificant reversion to original reactants in 
buffered solution (pH 7.4) at room temperature.  Although AEME exhibited retro release of 
GSH over time, this amount approximated to only 0.25% loss over 4 hours.  In general, the 
measured stability at physiological pH suggests that these metabolites, or their mercapturic 
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acid derivatives, are favorable, stable candidates for detection in human subjects.  Arecoline-
NAC and arecaidine-NAC have been found in arecoline-dosed rats (64).  Currently, there are 
no documented peer-reviewed articles, to our knowledge, reporting the identification of 
AEME-SG, AEME-NAC or related conjugates in human crack cocaine users.     
 Glutathione conjugates formed in vivo are enzymatically converted to mercapturic acid 
derivatives prior to excretion in the urine (75).  Therefore, if AEME is conjugated to AEME-
SG in vivo, then AEME-SG would be partially metabolized to AEME-NAC.  Our method 
including SPE clean-up followed by LC-MS, was developed to detect the AEME mercapturate 
in the urine of known free-base cocaine users.  In two urine samples (both positive for AEME 
and cocaine by LC-MS) from multiple drug overdose victims we failed to identify AEME-
NAC by direct-injection ESI-MS, LC-MS or LC-MS/MS.   
 Several pitfalls exist that potentially deter the detection of AEME-NAC in human urine.  
Firstly, the limit of detection of AEME-NAC on the more sensistive, quadrupole LC-MS 
system (Water, Micromass) was approximately 2.0 ng.  Perhaps, AEME-NAC was present in 
the urine, but existing in the picogram range, which is clearly below our detection limit.  Also, 
the inherent problems of ion suppression during ESI-MS analysis can impede nanoscale or 
lower detection of analytes (130).   
 The extent of free-base cocaine abuse is also a concern for analysis.  We were unable to 
determine from the case history data if the decedents under investigation were chronic or 
acute free-base cocaine users.  The literature suggests that up to 5% of cocaine is converted to 
AEME (42), leaving only a small amount of AEME available in vivo to conjugate with GSH.  
Therefore, the identification of AEME-SG in the bile or AEME-NAC in the urine of human 
subjects may indicate chronic cocaine use, a potentially useful piece of evidence in judicial 
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proceedings.  Several conservative calculations, starting with a solo free-base cocaine dose of 
100 mg, results in the formation of roughly 33 ng/mL of AEME-NAC in the urine, assuming 
normal hepatic and renal function with a total urine volume of 1.5 L (131).  More frequent 
crack cocaine use, obviously, would result in greater accumulation of AEME conjugates, 
leading to easier detection of these metabolites.  
 AEME is also chemically and enzymatically hydrolyzed to AE (46,56), a less reactive 
compound with GSH based on our preliminary findings (data not shown).  A possible 
explanation of the reduced reactivity of AE, containing a carboxylic acid moiety, includes the 
possible decreased stability of the resulting carbanion of AE-SG, leading to increased 
retrogression.  In fact, arecaidine, the hydrolysis product of arecoline and chemically similar to 
AE, reacted much slower with GSH and NAC than arecoline, partly due to the relative 
instability of the arecaidine-thiol products (64).  Moreover, AEME is significantly converted in 
vivo to AE, deterring contributable conjugation to AEME-SG (and later degradation, followed 
by acetylation to AEME-NAC) in free-base cocaine users.   
 The OCME of West Virginia detected cotinine, a nicotine metabolite with an 
approximately 8-fold greater plasma half-life than nicotine (132), in one decedents urine we 
analyzed for the presence of AEME-NAC, suggesting that this individual was a smoker.  
Benzo(a)pyrene is a polycyclic aromatic hydrocarbon (PAH) contained in inhaled mainstream 
tobacco smoke and capable of inducing Phase I and Phase II mRNAs and their corresponding 
proteins, including isoforms of GSTs (133).  Furthermore, nicotine induced mitochondrial 
GST A4-4 activity in the rat brain (134).  Another study found a weak, positive correlation 
between the number of cigarettes smoked per subject and GST activity of human lung tissue 
(135).  Although Graziano and co-workers (136) failed to report an increase in GST activity in 
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laboratory rats nasally exposed to cigarette smoke, they did conclude that smoking reduced 
hepatic glutathione content by almost 15%.  Moreover, they suggest that smokers are 
potentially less capable of detoxifying xenobiotics by GSH conjugation mechanisms (136).   
 Evaluated together, this conglomerate of literature reports suggests that nicotine or 
metabolites of tobacco smoking influence GST activity and/or the normal capacity to detoxify 
electrophilic compounds.  Therefore, the decedent who smoked may have rapidly created 
AEME-SG in vivo and excreted the mercapturate before expiring, after which the urine was 
collected.  On the other hand, it is also possible that the decedent had decreased hepatic GSH 
stores from chronic nicotine exposure, resulting in very minor or no appreciable levels of the 
GSH and NAC conjugates in his urine.       
 Finally, consider an additional mention regarding the potential detection of AEME-
NAC in biological fluids.  Forensic laboratories commonly employ GC-MS for analysis of 
biological fluids (137).  Furthermore, the aforementioned conjugates contain a peptide-like 
moiety that is susceptible to degradation upon thermal analysis, such as GC-MS, and more 
appropriately analyzed on a less thermal system, such as LC-MS.  Nonetheless, the potential 
exists for these conjugates as unique, forensic markers.  With significant concerns of 
artifactually producing AEME during GC-MS analysis of cocaine (36) and more recently 
AEEE from cocaethylene (138) and AE from benzoylecgonine, ecgonine or m-
hydroxybenzoylecgonine (37), the time is ripe for the identification of novel markers of 
smoked cocaine use. 
 As mentioned earlier, stable glutathione conjugates formed in vivo are potentially 
cytotoxic (75).  Less stable adducts can release the parent, electrophilic compound at target 
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sites and exhibit toxicity (83).  One pertinent example, discussed in more detail here, is the 
loop diuretic, ethacrynic acid, that readily forms conjugates with glutathione (85).   
 An interesting but deleterious adverse drug reaction to ethacrynic acid therapy is the 
development of ototoxicity, often co-existing with renal impairment (139).  As little as 100 mg 
EA orally or 50 mg IV sodium ethacrynate have produced severe, transient hearing losses 
(139).  Approximately 20-30% of administered EA is converted to the cysteine conjugate of 
EA (EA-cys), a metabolite of EA-SG (139).  Some experimental evidence exists that suggests 
that EA-cys is the causative agent in EA induced ototoxicity (139-142).   
 For instance, EA (5.0 mg/kg) and EA-cys (2.0 mg/kg) were administered intravenously 
to healthy, adult cats (139).  Ototoxicity was measured by the extent of cochlear N1 depression.  
EA-cys exhibited an approximately 4-fold greater potency in producing N1 depression than EA 
alone (139).  Additionally, EA exhibited a longer latent period until the development of N1 
depression, suggesting EA is converted to EA-cys before ototoxic effects occur (139). 
 Another study revealed that EA-cys (2.4 mg/kg) administered IV to adult cats was more 
potent in inducing ototoxicity than EA (5.0 mg/kg) or furosemide (12.0 mg/kg), a loop diuretic 
chemically similar to EA (140).  The duration of ototoxicity induced by EA or EA-cys was 
prolonged in comparison to furosemide (140).  Similar to an earlier study, EA-cys displayed 
increased potency in inducing cochlear N1 depression than EA (140). 
 These studies indicate that EA-cys may be a directly toxic agent to cochlear cells.  In 
fact, EA-cys (MK-597) was withdrawn from clinical trials due to a high incidence of hearing 
loss (143).  Contrary, another theory has been proposed that may explain the enhanced 
ototoxicity seen with EA-cys (144).  EA binds plasma proteins nearly two fold greater than 
equal concentrations of EA-cys at 37°C (142).  Under physiological conditions, EA-cys can 
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spontaneously reverse to regenerate EA (142).  Therefore, free EA-cys, which is less 
extensively bound to plasma proteins, can conceivably liberate more EA at cochlear sites and 
exert toxicity (145). 
 The in vitro conversion of AEME to AEME-SG is documented in this report.  Although 
likely, whether AEME is conjugated to AEME-SG in vivo and subsequently degraded to 
AEME-cys or AEME-NAC remains to be detected in free-base cocaine users.  AEME-cys, if 
present, may play a role in cocaine related hearing losses in infants and newborns.  Several 
studies have documented significant hearing losses in cocaine exposed unborn children (146-
148).  Whether AEME, AEME-SG or AEME-cys are toxic to human cochlear cells remains to 
be studied. 
 Besides hearing loss, cocaine also exhibits pulmonary toxicities that are well 
documented (9,149,150).  The exact mechanism(s) of injury, however, are still largely 
unexplained.  Current literature reports conflict on the pulmonary effects of AEME.  One study 
reputes that AEME relaxes airway smooth muscle (58), while another reports suggests that it 
may play a role in bronchoconstriction observed in crack smokers (59).   
 We attempted to provide initial evidence regarding the likely cytotoxic effects of 
AEME and other pyrolysis products.  Using a trypan blue exclusion assay, we report that AE, 
AEME and to a lesser extent, AEEE are toxic to A549 lung fibroblast cells following a 24 hour 
incubation.  Using flow cytometry (151,152), we attempted to measure A549 cytotoxicity, but 
obtained significant cellular death with DMSO (2%) control, leading to weak comparisons with 
cells spiked with cocaine or pyrolysis products.  DMSO, a documented membrane transport 
facilitator of low molecular weight, uncharged molecules (153), likely increased cellular 
uptake of propidium iodide (PI), leading to enhanced fluorescence not necessarily indicative of 
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cellular death.  Actual reports of DMSO increasing PI permeability in cell lines are largely 
anecdotal and not well documented, although it is suggested to keep DMSO concentration ≤ 
0.1% (personal communication with Dr. Cynthia Cunningham, West Virginia University).   
 We did observe, using flow cytometry, enhanced toxicity of pyrolysis products to A549 
cells as compared to cocaine alone, a known toxin (Table 3.2).  Furthermore, the addition of 
NAC appeared to reduce the cytotoxicity of AEME and AEEE but not with AE, suggesting 
that a likely mechanism of toxicity involves the Michael addition of electrophilic pyrolysis 
products to reactive groups on proteins.  Another explanation, although not studied by us, 
implies that these alkaline thermolytic products, containing an oxidizable tertiary amine group, 
may form reactive N-oxides.  Further experimentation is needed to clarify the exact mechanism 
of injury. 
 An interesting chapter evolved from our studies.  Studies suggest that 60-85% of 
cocaine abusers also abuse alcohol, and concomitant consumption of cocaine and alcohol is 
common (26).  The Drug Abuse Warning Network (DAWN) has consistently reported that the 
co-administration of cocaine and ethyl alcohol is the number one drug-drug interaction leading 
to emergency room admissions (154).  The co-administration of cocaine and ethanol forms the 
ethylated product, cocaethylene.  In an analogous fashion, AEME forms AEEE in the presence 
of ethanol when studied in rat liver microsomes (56).  The idea of AEEE as a metabolite of 
cocaine and ethanol co-abuse has only been proposed earlier (57). 
 We report the identification of AEEE in a human subject who co-abused crack cocaine 
and ethanol.  GC-MS was initially used to detect AEEE in 1 mL urine sample.  However, the 
amount of AEEE in the urine quantified by standard curve on GC-MS was inflated due to 
pyrolysis of cocaethylene to AEEE in the heated GC injector port.  Several reports have 
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documented the analogous generation of an artifact AEME peak from pyrolysis of cocaine 
during GC-MS analysis (36,155).  Furthermore, artifact AEME production is linearly 
dependent on cocaine concentration and attenuated by the use of a clean insert liner (36).  
Identification of AEME by GC-MS analysis is equivocal because of the potential for artifactual 
production in heated injector ports of gas chromatographs.  Analogously, application of GC-
MS methods to the identification of AEEE in the presence of cocaethylene is also equivocal. 
 A more reliable alternative to the recently reported internal or external standardization 
method (36) is the use of a less thermolytically driven analytical step, such as LC-MS.  Our 
LC-MS assay detected AEEE in urine following SPE at a concentration of approximately  
50 ng/mL.  This extrapolated value estimates the relative amount of AEEE in the urine and 
further confirms its presence.  The concentrations of cocaine and cocaethylene in the sample 
were substantially greater than their respective thermolytic products, but were about equally 
concentrated.  The data suggests that the transesterification of cocaine to cocaethylene 
proceeds at a faster rate than the analogous reaction of AEME to AEEE.  Furthermore, it may 
be likely, although not proven by our investigations, that cocaine is a better substrate than 
AEEE for hCE-1, the putative transesterification enzyme (19,51,156,157).   
 Our multistage mass spectrometry LC-MS analysis represents a third analytical 
approach for identifying AEEE in the urine sample.  Our analysis found that the electrospray 
ionization process also fragments cocaethylene to yield an ion of the same molecular weight as 
protonated AEEE, but LC was capable of separating the ions.  These findings point to the need 
for LC separation of cocaethylene from AEEE to correctly identify AEEE in future samples.  
Although GC-MS fragmentation pathways are more reliable and more commonly employed in 
 116
forensic laboratories, our concern for artifactual production of AEEE warrants confirmation by 
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5.1 Future Directions 
 Some of the future work outlined below was speculated earlier in the previous chapter.  
Since our outlined studies failed to identify the AEME mercapturate in the urine, a more 
sensitive method is needed to evaluate numerous biological matrices (urine, bile, blood) of 
known free-base cocaine smokers for AEME-SG, AEME-NAC or other related conjugates.  In 
addition, the availability of urine (or other fluid) with case evaluations from many crack 
cocaine users would allow an interesting side experiment that investigates the potential 
relationship between extent of cocaine use and detection of conjugates.  Arecoline, a practice 
compound chemically similar to AEME and a drug of abuse in the Orient, also forms GSH 
adducts (and derivatives) in rats, which may be detected in the urine and bile of human betel 
nut users.   
 The literature conflicts on the particular effects of arecoline on GST activity; therefore, 
a potential future study could evaluate whether arecoline is a substrate for cytosolic GSTs.  
Similarly, since our studies presented here only identify AEME as a mixed inhibitor of 
cytosolic GSTs, future studies would determine if AEME is an inhibitor of specific GST 
isoforms, such as alpha or pi.  Following which, in silico modeling could be applied to examine 
the orientation of AEME within the H (hydrophobic or electrophilic) binding site of the GST 
isoform(s).  Also interesting includes a series of studies evaluating if the AEME-SG conjugate 
also inhibits GSTs, and if so, can the conjugate bind to both substrate sites within the active 
site of GSTs. 
 We provided initial cytotoxic data regarding several cocaine pyrolysis products 
(AEME, AEEE and AE).  Continued research with flow cytometry and other applicable 
techniques using lung fibroblasts and other pertinent cell lines (i.e. myocytes and renocytes) 
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would assist in unraveling potential mechanisms of injury previously unexplained with free-
base cocaine abuse.  Finally, the pharmacology of AE is currently unknown and remains an 
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6.1 Summary and Conclusions 
 Smoking continues today as a major route of abuse for psychoactive drugs, leading to 
the formation of potentially toxic thermolytic products.  The pyrolysis of cocaine to AEME has 
been well-documented since the early 1990s.  Chemically, we maintain that AEME contains 
an electrophilic α,β-unsaturated carbonyl functional group, and we were successful in 
documenting the chemical reactivity of AEME with glutathione, a nucleophilic compound 
ubiquitously occurring in humans.  Glutathione and mercapturic acid derivatives of AEME 
were synthesized.  Also, AEME depleted glutathione concentrations over 4 hours in vitro and 
slowed the chemical conversion of DCNB to DCNB-SG over 20 minutes.  However, our data 
suggests that AEME reacts modestly with glutathione, as compared to arecoline and ethacrynic 
acid, indicating that AEME conjugates are minor metabolites of free-base cocaine use and 
potentially undetectable. 
 We are unable, at this time, to conclude that AEME is a substrate for cytosolic GSTs, 
the soluble enzymes that catalyze glutathione addition to electrophilic compounds.  AEME did 
block apparent cytosolic GST activity.  Our studies displayed a significant reduction of GST 
activity in the presence of AEME after a 20 hour co-incubation with human liver cytosol.  
More detailed kinetic studies proved that AEME inhibits cytosolic GST activity by a mixed-
linear model, but retains a weak inhibition constant.  We also observed in cellular toxicity 
studies using trypan blue exclusion and flow cytometry, that AEME and other pyrolysis 
products exhibited a greater toxicity to A549 lung fibroblasts than equally concentrated 
cocaine.  AEME, AE, AEEE and related conjugates are potentially novel players in the 
sequelae of pulmonary toxicity exhibited in crack cocaine users. 
 122
 Finally, we detected AEEE in the urine of a drug overdose victim with a history of drug 
abuse by GC-MS, LC-MS, and LC-MS/MS.  To our knowledge, this is the first documented 
report of the identification of this metabolite in humans.  AEEE is a potential additional 
forensic marker, besides cocaethylene and ecgonine ethyl ester, for the detection of crack 
cocaine abused concomitantly with ethanol.  The inherent dangers of erroneously identifying 
AEEE in a biological sample, also containing cocaethylene, by GC-MS analytical methods 
exists today in forensic laboratories.  Therefore, our alternative LC-MS and LC-MS/MS 
methods, capable of chromatographically separating artifactually created compound from 
authentic metabolite present in urine, provide the basis for a useful analytical method in 
forensic cases involving suspected free-base cocaine/ethanol use. 
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